Antigen binding molecule specifically binding to EGFR and MUC1, drug conjugate thereof, and medical use thereof

MYPI2025006194A0Undetermined Publication Date: 2024-10-13SHANGHAI HENGRUI PHARM CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025006194
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-21
Filing Date
2024-04-12
Publication Date
2024-10-13

AI Technical Summary

Technical Problem

Existing antibodies targeting MUC1-N are ineffective and there is limited data on antibodies targeting MUC1-C. EGFR monoclonal antibodies have safety issues, which limits their efficacy, and dual antibodies bind too much to normal tissues, causing side effects. and poor efficacy.

Method used

Develop an anti-MUC1 antibody or its antigen-binding fragment that specifically binds to MUC1-C of human MUC1 and an antigen-binding molecule that binds to EGFR and MUC1 to target dual-expressing tumor cells, reduce binding to normal tissue, and interact with Small molecule toxin conjugation to improve efficacy.

Benefits of technology

It improves the specific attack ability against tumor cells, reduces the side effects on normal tissues, expands the indications, and enhances the efficacy and safety of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025006194_DRAWING_001
    Figure PI2025006194_DRAWING_001
  • Figure PI2025006194_DRAWING_002
    Figure PI2025006194_DRAWING_002
  • Figure PI2025006194_DRAWING_003
    Figure PI2025006194_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to an antigen binding molecule specifically binding to EGFR and MUC1, a drug conjugate thereof, and a medical use thereof. Specifically, the present invention relates to an anti-MUC1 antibody or an antigen binding fragment thereof, an anti-EGFR antibody or an antigen binding fragment thereof, an antigen binding molecule specifically binding to EGFR and MUC1, a drug conjugate thereof, and a medical use thereof. FIGURE 1
Need to check novelty before this filing date? Find Prior Art

Description

Antigen binding molecules specifically binding to EGFR and MUC1, drug conjugates thereof, and medical uses thereof

[0001] This disclosure claims priority to CN202310394160.8 filed on April 13, 2023 and CN202311772280.3 filed on December 21, 2023. Technical Field

[0002] The present disclosure belongs to the field of biotechnology and relates to anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and conjugates thereof with drugs and their medical uses. Background Art

[0003] The statements herein merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0004] MUC1 is a transmembrane glycoprotein with abundant glycosylation. Its extracellular region is a dimer formed by two chains interacting through hydrogen bonds: MUC1-N and MUC1-C. MUC1-N is rich in O-glycosylation and has a small amount of N-glycosylation. Its amino acid backbone is composed of multiple repeats of VNTRs. MUC1-C comprises an extracellular domain, a transmembrane domain, and an intracellular domain.

[0005] In normal tissues, MUC1 is present in its full-length form at the apical end of epithelial cells, while EGFR is present at the basal end. Tumor cells lose this apical-basal polarity, resulting in a uniform distribution of EGFR and MUC1 on the cell surface. This phenomenon brings EGFR and MUC1 closer together. Furthermore, the O-glycosylation of MUC1-N on tumor cells becomes significantly less frequent. As tumors progress, MUC1-N is shed under the catalysis of inflammatory cytokine-related enzymes in the tumor microenvironment, exposing MUC1-C.

[0006] MUC1-N can shed and release into the bloodstream, causing off-target effects on MUC1-N-targeted antibodies. This has been the primary reason for the poor efficacy of previous MUC1-N-targeted antibodies in clinical practice. Clinical data for antibodies targeting MUC1-C are extremely limited. The disclosed MUC1-C-targeted antibody, which has no off-target effects, could serve as a beneficial supplement to MUC1-C antibodies.

[0007] Because EGFR is also expressed at certain levels in normal tissues, clinically available EGFR monoclonal antibodies have significant safety concerns, limiting their efficacy. The disclosed EGFR-MUC1 bispecific antibody preferentially targets dual-expressing tumor cells, reducing antibody binding to normal tissues. Simultaneously, it is coupled with a small molecule toxin, minimizing side effects while improving efficacy. Furthermore, compared to EGFR or MUC1 monoclonal antibodies, the EGFR-MUC1 bispecific antibody has a broader range of indications and patient populations.

[0008] Summary of the Invention

[0009] The present disclosure provides an anti-MUC1 antibody or an antigen-binding fragment thereof that specifically binds to MUC1-C of human MUC1 but does not bind to MUC1-N.

[0010] The present disclosure provides an anti-MUC1 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein:

[0011] a. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 4, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 5; or

[0012] b. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 of any one of SEQ ID NO: 6 or 47, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 7; or

[0013] c. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 8, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 9; or

[0014] d. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 of any one of SEQ ID NO: 63, 10 or 64, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 11.

[0015] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof as described above, wherein:

[0016] a. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 4, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 5; or

[0017] b. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 6, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 7; or

[0018] c. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 8, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 9; or

[0019] d. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 63, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 11.

[0020] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0021] The HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 47, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 7.

[0022] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0023] The HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 10, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 11.

[0024] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0025] The HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 64, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 11.

[0026] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof of any of the preceding items, the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region and the LCDR1, LCDR2 and LCDR3 of the light chain variable region are defined according to the same numbering convention selected from Kabat, IMGT, Chothia, AbM and Contact.

[0027] In some embodiments, the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region and the LCDR1, LCDR2 and LCDR3 of the light chain variable region are defined according to the Kabat numbering convention. In some embodiments, the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region and the LCDR1, LCDR2 and LCDR3 of the light chain variable region are defined according to the IMGT numbering convention. In some embodiments, the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region and the LCDR1, LCDR2 and LCDR3 of the light chain variable region are defined according to the Chothia numbering convention. In some embodiments, the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region and the LCDR1, LCDR2 and LCDR3 of the light chain variable region are defined according to the AbM numbering convention. In some embodiments, the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region and the LCDR1, LCDR2 and LCDR3 of the light chain variable region are defined according to the Contact numbering convention.

[0028] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0029] a. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; or

[0030] b. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 18, HCDR2 comprises the amino acid sequence of SEQ ID NO: 19, and HCDR3 comprises the amino acid sequence of any one of SEQ ID NO: 20 or 113, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 21, LCDR2 comprises the amino acid sequence of SEQ ID NO: 22, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 23; or

[0031] c. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24, HCDR2 comprises the amino acid sequence of SEQ ID NO: 25, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 26, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 27, LCDR2 comprises the amino acid sequence of SEQ ID NO: 28, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 29; or

[0032] d. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, HCDR2 comprises the amino acid sequence of SEQ ID NO: 31, and HCDR3 comprises the amino acid sequence of any one of SEQ ID NOs: 114, 32 or 115, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33, LCDR2 comprises the amino acid sequence of SEQ ID NO: 34, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 35.

[0033] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0034] a. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 12, HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 15, LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 17;

[0035] b. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 18, HCDR2 comprises the amino acid sequence of SEQ ID NO: 19, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 20, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 21, LCDR2 comprises the amino acid sequence of SEQ ID NO: 22, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 23; or

[0036] c. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24, HCDR2 comprises the amino acid sequence of SEQ ID NO: 25, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 26, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 27, LCDR2 comprises the amino acid sequence of SEQ ID NO: 28, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 29; or

[0037] d. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, HCDR2 comprises the amino acid sequence of SEQ ID NO: 31, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 114, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33, LCDR2 comprises the amino acid sequence of SEQ ID NO: 34, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 35.

[0038] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof of any of the preceding items, wherein HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 18, HCDR2 comprises the amino acid sequence of SEQ ID NO: 19, and HCDR3 comprises the amino acid sequence of any one of SEQ ID NO: 113, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 21, LCDR2 comprises the amino acid sequence of SEQ ID NO: 22, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 23.

[0039] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof of any of the preceding items, wherein HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, HCDR2 comprises the amino acid sequence of SEQ ID NO: 31, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 115, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33, LCDR2 comprises the amino acid sequence of SEQ ID NO: 34, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 35.

[0040] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof of any of the preceding items, wherein HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, HCDR2 comprises the amino acid sequence of SEQ ID NO: 31, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 32, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33, LCDR2 comprises the amino acid sequence of SEQ ID NO: 34, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 35.

[0041] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof of any of the preceding items, wherein HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 17.

[0042] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody. In some embodiments, it is a chimeric antibody or a humanized antibody. In some embodiments, it is a humanized antibody.

[0043] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items comprises a framework region (FR) of a human antibody.

[0044] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0045] a. the heavy chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 36, 37, or 38, and the light chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 39, 40, 41, or 42; or

[0046] the heavy chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO:4, and the light chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO:5; or

[0047] b. the heavy chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 43, 44, 45, 46, 47, 48, or 49, and the light chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 50, 51, or 52; or

[0048] the heavy chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO:6, and the light chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO:7; or

[0049] c. the heavy chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 53, 54, or 55, and the light chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 56, 57, 58, or 59; or

[0050] the heavy chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO:8, and the light chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO:9; or

[0051] d. the heavy chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 63, 60, 61, 62, or 64, and the light chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 67, 68, 65, or 66; or

[0052] The heavy chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 10, and the light chain variable region comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 11.

[0053] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, the heavy chain variable region has FR1, FR2, FR3 derived from IGHV1-46*01 and FR4 derived from IGHJ6*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 28S, 38K, 40R, 48I, 71A, 73K, 76D and 82aR; and / or the light chain variable region has FR1, FR2, FR3 derived from IGKV1-39*01, 1GKV6-21*02 or IGKV3-11*01 and FR4 derived from IGKJ4*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 3V, 43S, 47W, 49Y and 60G. In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof, wherein the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the FRs of the heavy chain variable region comprise one or more amino acid substitutions selected from the group consisting of 1E, 28S, 38K, 40R, 48I, 71A, 73K, 76D and 82aR; and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17, and the FRs of the light chain variable region comprise one or more amino acid substitutions selected from the group consisting of 3V, 43S, 47W, 49Y and 60G. In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof, wherein the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the FRs of the heavy chain variable region comprise one or more amino acid substitutions selected from the group consisting of 1E, 28S, 38K, 40R, 48I, 71A, 73K, 76D and 82aR; and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17, and the FRs of the light chain variable region comprise one or more amino acid substitutions selected from the group consisting of 3V, 43S and 47W.In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof comprises: HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the FRs of the heavy chain variable region comprise amino acid substitutions of 1E, 71A, 73K, and 76D; and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 17, and the FRs of the light chain variable region comprise amino acid substitutions of 43S and 47W. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0054] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, the heavy chain variable region has FR1, FR2, FR3 derived from IGHV1-46*01 and FR4 derived from IGHJ6*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 28R, 30I, 39E, 40R, 43H, 69F, 71A, 76N, 82bQ, 83T and 84N; and / or the light chain variable region has FR1, FR2, FR3 derived from IGKV4-1*01 or IGKV3-11*01 and FR4 derived from IGKJ4*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1D, 4M, 45K, 68R and 83V. In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region HCDR1 comprising the amino acid sequence of SEQ ID NO: 18, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 20 or 113, and the heavy chain variable region FR comprises one or more amino acid substitutions selected from the group consisting of 1E, 28R, 30I, 39E, 40R, 43H, 69F, 71A, 76N, 82bQ, 83T, and 84N; and a light chain variable region LCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 22, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the light chain variable region FR comprises one or more amino acid substitutions selected from the group consisting of 1D, 4M, 45K, 68R, and 83V. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0055] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, the heavy chain variable region has FR1, FR2, FR3 derived from IGHV1-3*01 and FR4 derived from IGHJ6*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 2I, 12V, 40R, 44G, 47Y, 48I, 69L, 71V and 76R; and / or the light chain variable region has FR1, FR2, FR3 derived from IGKV1-39*01 and FR4 derived from IGKJ4*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 4L, 36F, 42T, 43S, 47W, 60P, 70S and 75V. In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 26, and a heavy chain variable region FR comprising one or more amino acid substitutions selected from the group consisting of 1E, 2I, 12V, 40R, 44G, 47Y, 48I, 69L, 71V, and 76R; and a light chain variable region LCDR1 comprising the amino acid sequence of SEQ ID NO: 27, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 29, and a light chain variable region FR comprising one or more amino acid substitutions selected from the group consisting of 4L, 36F, 42T, 43S, 47W, 60P, 70S, and 75V. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0056] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, the heavy chain variable region has FR1, FR2, FR3 derived from IGHV1-3*01 and FR4 derived from IGHJ1*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 12V, 20M, 24T, 40R, 44G, 48I, 69L and 71S; and / or the light chain variable region has FR1, FR2, FR3 derived from IGKV1-39*01 and FR4 derived from IGKJ4*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 4L, 36L, 39E, 42G, 44I, 46R, 60K, 66R, 69S and 71Y. In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof, wherein the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:30, the HCDR2 comprises the amino acid sequence of SEQ ID NO:31, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:114, 32 or 115, and the FRs of the heavy chain variable region comprise one or more amino acid substitutions selected from the group consisting of 12V, 20M, 24T, 40R, 44G, 48I, 69L and 71S; and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:33, the LCDR2 comprises the amino acid sequence of SEQ ID NO:34, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:35, and the FRs of the light chain variable region comprise one or more amino acid substitutions selected from the group consisting of 4L, 36L, 39E, 42G, 44I, 46R, 60K, 66R, 69S and 71Y. In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof, wherein the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:30, the HCDR2 comprises the amino acid sequence of SEQ ID NO:31, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:114, and the FRs of the heavy chain variable region comprise one or more amino acid substitutions selected from the group consisting of 12V, 20M, 24T, 40R, 44G, 48I, 69L, and 71S; and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:33, the LCDR2 comprises the amino acid sequence of SEQ ID NO:34, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:35, and the FRs of the light chain variable region comprise one or more amino acid substitutions selected from the group consisting of 4L, 36L, 39E, 42G, 44I, 46R, 60K, 66R, 69S, and 71Y.In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region HCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 115, and a heavy chain variable region FR comprising one or more amino acid substitutions selected from the group consisting of 12V, 20M, 24T, 40R, 44G, 48I, 69L, and 71S; and a light chain variable region LCDR1 comprising the amino acid sequence of SEQ ID NO: 33, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 35, and a light chain variable region FR comprising one or more amino acid substitutions selected from the group consisting of 4L, 36L, 39E, 42G, 44I, 46R, 60K, 66R, 69S, and 71Y. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0057] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0058] a. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39 or 40; or

[0059] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 37, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39 or 40; or

[0060] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 5; or

[0061] b. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 43, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 50; or

[0062] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 44, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 51; or

[0063] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 45, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 50 or 51; or

[0064] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 46, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 51; or

[0065] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 6, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 7; or

[0066] c. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 53, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 56, 57 or 59; or

[0067] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 54, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 57; or

[0068] or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 8, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 9; or

[0069] d. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 60, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 65 or 68; or

[0070] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 61, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 65, 66, 67 or 68; or

[0071] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 67 or 68; or

[0072] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 10, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 11.

[0073] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0074] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39; or

[0075] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 40; or

[0076] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 37, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39; or

[0077] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 37, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 40; or

[0078] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO:4, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:5.

[0079] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof according to any of the preceding items, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:39.

[0080] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0081] a. the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 36, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 39 or 40; or

[0082] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 37, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 39 or 40; or

[0083] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 4, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 5; or

[0084] b. the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 50; or

[0085] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 51; or

[0086] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 50 or 51; or

[0087] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 51; or

[0088] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 7; or

[0089] c. the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 53, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 56, 57 or 59; or

[0090] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 54, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 57; or

[0091] or the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 8, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 9; or

[0092] d. the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 60, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 65 or 68; or

[0093] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 61, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 65, 66, 67 or 68; or

[0094] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 63, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 67 or 68; or

[0095] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 11.

[0096] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items, wherein:

[0097] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 36, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 39; or

[0098] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 36, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 40; or

[0099] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 37, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 39; or

[0100] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 37, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 40; or

[0101] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 4, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 5.

[0102] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof according to any of the preceding items, wherein the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 36, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 39.

[0103] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items is an antibody fragment; in some embodiments, the antibody fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, scFv, dsFv and dAb.

[0104] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items comprises a heavy chain constant region and a light chain constant region. In some embodiments, the heavy chain constant region is a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region. In some embodiments, the light chain constant region is a human kappa or lambda light chain constant region.

[0105] In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 69 or 186, and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 70.

[0106] In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:69, and the light chain constant region comprises the amino acid sequence of SEQ ID NO:70.

[0107] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items comprises a heavy chain and a light chain, wherein:

[0108] a. the heavy chain comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98% or 99%) identical to SEQ ID NO: 71, 73, 75 or 77, and the light chain comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98% or 99%) identical to SEQ ID NO: 72, 74, 76 or 78; or

[0109] b. the heavy chain comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 79, 81, 83, 85, or 87, and the light chain comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 80, 82, 84, 86, or 88; or

[0110] c. the heavy chain comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 89, 91, 93, or 95, and the light chain comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 90, 92, 94, or 96; or

[0111] d. the heavy chain comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, or 111, and the light chain comprises an amino acid sequence that is at least 70% (e.g., at least 70%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, or 112.

[0112] In some embodiments, the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items comprises a heavy chain and a light chain, wherein:

[0113] a. the amino acid sequence of the heavy chain is shown in SEQ ID NO: 71, and the amino acid sequence of the light chain is shown in SEQ ID NO: 72; or

[0114] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 73, and the amino acid sequence of the light chain is shown in SEQ ID NO: 74; or

[0115] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 75, and the amino acid sequence of the light chain is shown in SEQ ID NO: 76; or

[0116] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 77, and the amino acid sequence of the light chain is shown in SEQ ID NO: 78;

[0117] b. the amino acid sequence of the heavy chain is shown in SEQ ID NO: 79, and the amino acid sequence of the light chain is shown in SEQ ID NO: 80; or

[0118] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 81, and the amino acid sequence of the light chain is shown in SEQ ID NO: 82; or

[0119] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 83, and the amino acid sequence of the light chain is shown in SEQ ID NO: 84; or

[0120] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 85, and the amino acid sequence of the light chain is shown in SEQ ID NO: 86; or

[0121] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 87, and the amino acid sequence of the light chain is shown in SEQ ID NO: 88;

[0122] c. the amino acid sequence of the heavy chain is shown in SEQ ID NO: 89, and the amino acid sequence of the light chain is shown in SEQ ID NO: 90; or

[0123] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 91, and the amino acid sequence of the light chain is shown in SEQ ID NO: 92; or

[0124] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 93, and the amino acid sequence of the light chain is shown in SEQ ID NO: 94; or

[0125] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 95, and the amino acid sequence of the light chain is shown in SEQ ID NO: 96;

[0126] d. the amino acid sequence of the heavy chain is shown in SEQ ID NO: 97, and the amino acid sequence of the light chain is shown in SEQ ID NO: 98; or

[0127] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 99, and the amino acid sequence of the light chain is shown in SEQ ID NO: 100; or

[0128] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 101, and the amino acid sequence of the light chain is shown in SEQ ID NO: 102; or

[0129] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 103, and the amino acid sequence of the light chain is shown in SEQ ID NO: 104; or

[0130] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 105, and the amino acid sequence of the light chain is shown in SEQ ID NO: 106; or

[0131] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 107, and the amino acid sequence of the light chain is shown in SEQ ID NO: 108; or

[0132] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 109, and the amino acid sequence of the light chain is shown in SEQ ID NO: 110; or

[0133] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 111, and the amino acid sequence of the light chain is shown in SEQ ID NO: 112.

[0134] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof according to any of the preceding items comprises a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain is shown in SEQ ID NO: 71, and the amino acid sequence of the light chain is shown in SEQ ID NO: 72.

[0135] In some embodiments, the present disclosure also provides an isolated anti-MUC1 antibody or an antigen-binding fragment thereof that competes with the anti-MUC1 antibody of any of the preceding items for binding to human MUC1.

[0136] In some embodiments, the isolated anti-MUC1 antibodies or antigen-binding fragments thereof disclosed herein are expressed in a concentration of less than 5×10 -8 M (e.g. less than 4×10 -8 M, less than 3×10 -8 M, less than 2.5×10 -8 M, less than 2×10-8 M, less than 1.5×10 -8 M, less than 1×10 -8 M, less than 9×10 -9 M, less than 8×10 -9 M, less than 7×10 -9 M, less than 6×10 -9 M, less than 5×10 -9 M, less than 4×10 -9 M, less than 3×10 -9 M, less than 2×10 -9 M) binds to human MUC1 with KD values ​​measured by Biacore.

[0137] In another aspect, the present disclosure provides an anti-EGFR antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein:

[0138] a. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 116, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, 128, 130 or 131, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0139] b. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 126 or 133, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0140] c. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 116, HCDR2 comprises the amino acid sequence of SEQ ID NO: 127, 132 or 134, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0141] d. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 126, HCDR2 comprises the amino acid sequence of SEQ ID NO: 127, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121;

[0142] e. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128, 129, 130 or 131, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0143] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof as described above comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein:

[0144] a. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 116, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0145] b. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 126, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 128 or 130, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0146] c. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 133, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0147] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 116, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0148] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region and the LCDR1, LCDR2 and LCDR3 of the light chain variable region are defined according to the same numbering convention selected from Kabat, IMGT, Chothia, AbM and Contact. In some embodiments, they are defined according to the Kabat numbering convention. In some embodiments, they are defined according to the IMGT numbering convention. In some embodiments, they are defined according to the Chothia numbering convention. In some embodiments, they are defined according to the AbM numbering convention. In some embodiments, they are defined according to the Contact numbering convention.

[0149] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody. In some embodiments, it is a chimeric antibody or a humanized antibody. In some embodiments, it is a humanized antibody.

[0150] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items comprises a framework region (FR) of a human antibody.

[0151] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof according to any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 138, 135, 136, 137, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149;

[0152] Preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 138, 142, 144 or 147, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149;

[0153] More preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 138, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149.

[0154] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items is an antibody fragment; in some embodiments, the antibody fragment is selected from Fab, Fab′, F(ab′)2, Fd, Fv, scFv, dsFv and dAb.

[0155] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items comprises a heavy chain constant region and a light chain constant region. In some embodiments, the heavy chain constant region is a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region. In some embodiments, the light chain constant region is a human kappa or lambda light chain constant region. In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 69 or 186, and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 70. In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 69, and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 70.

[0156] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof of any of the preceding items comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 150, 151, 152, 154, 155, 156, 157, 158, 159, 160, 161, 162, or 163, and the light chain comprises the amino acid sequence of SEQ ID NO: 164;

[0157] Preferably, the heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 157, 159 or 162, and the light chain comprises the amino acid sequence of SEQ ID NO: 164;

[0158] More preferably, the heavy chain comprises the amino acid sequence of SEQ ID NO: 153, and the light chain comprises the amino acid sequence of SEQ ID NO: 164.

[0159] In some embodiments, the present disclosure also provides an isolated anti-EGFR antibody or an antigen-binding fragment thereof, which competes with the anti-EGFR antibody of any of the preceding items for binding to human EGFR.

[0160] In another aspect, the present disclosure provides an antigen binding molecule that specifically binds to EGFR and MUC1, comprising at least one antigen binding moiety that specifically binds to EGFR and at least one antigen binding moiety that specifically binds to MUC1, wherein the antigen binding moiety that specifically binds to EGFR comprises a heavy chain variable region EGFR-VH and a light chain variable region EGFR-VL, and the antigen binding moiety that specifically binds to MUC1 comprises a heavy chain variable region MUC1-VH and a light chain variable region MUC1-VL; wherein:

[0161] a. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, 128, 130 or 131, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0162] b. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126 or 133, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0163] c. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 127, 132 or 134, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0164] d. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 127, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0165] e. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128, 129, 130 or 131, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0166] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described above, wherein:

[0167] a. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0168] b. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128 or 130, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0169] c. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 133, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0170] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0171] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17.

[0172] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein:

[0173] the EGFR-VH comprising the amino acid sequence of SEQ ID NO: 138, 135, 136, 137, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148; and the EGFR-VL comprising the amino acid sequence of SEQ ID NO: 149;

[0174] Preferably, the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, 142, 144 or 147; and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149;

[0175] More preferably, the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138; and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149.

[0176] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36; and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39.

[0177] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the antigen binding moiety that specifically binds to EGFR or the antigen binding moiety that specifically binds to MUC1 each independently comprises a titin chain and an obscurin chain that can form a dimer (derived from WO2022237882A1).

[0178] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the titin chain comprises the amino acid sequence of SEQ ID NO: 165, and the obscurin chain comprises the amino acid sequence of SEQ ID NO: 166.

[0179] In some embodiments, the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items further comprises an Fc region, wherein the Fc region is preferably an IgG Fc region, further preferably an IgG1 Fc region; more preferably, the Fc region comprises one or more amino acid substitutions that can reduce the binding of the Fc region to the Fcγ receptor.

[0180] In some embodiments, the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items further comprises an Fc region, wherein the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that are capable of associating with each other, wherein the Fc1 and Fc2 each independently have one or more amino acid substitutions that reduce homodimerization of the Fc region. It should be understood that in the context of this application, when referring to Fc1 and Fc2, the function of the two is to form a dimer, and therefore Fc1 and Fc2 are interchangeable.

[0181] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the Fc1 has a protrusion structure according to the knob-and-mortar technique, and the Fc2 has a hole structure according to the knob-and-mortar technique; or, vice versa, the Fc2 has a protrusion structure according to the knob-and-mortar technique, and the Fc1 has a hole structure according to the knob-and-mortar technique.

[0182] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the Fc1 has a protrusion structure according to the knob-and-hole technique, and the Fc2 has a hole structure according to the knob-and-hole technique.

[0183] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the amino acid at position 358 of the Fc1 is C, the amino acid at position 370 is W; and the amino acid at position 357 of the Fc2 is C, the amino acid at position 374 is S, the amino acid at position 376 is A, and the amino acid at position 415 is V, numbering according to the EU index. Or, vice versa, the amino acid at position 358 of the Fc2 is C, the amino acid at position 370 is W; and the amino acid at position 357 of the Fc1 is C, the amino acid at position 374 is S, the amino acid at position 376 is A, and the amino acid at position 415 is V, numbering according to the EU index.

[0184] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the amino acid at position 358 of the Fc1 is C, the amino acid at position 370 is W; and the amino acid at position 357 of the Fc2 is C, the amino acid at position 374 is S, the amino acid at position 376 is A, and the amino acid at position 415 is V, numbering according to the EU index.

[0185] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the Fc1 comprises the amino acid sequence of SEQ ID NO: 169; the Fc2 comprises the amino acid sequence of SEQ ID NO: 170. Alternatively, vice versa, the Fc2 comprises the amino acid sequence of SEQ ID NO: 169; and the Fc1 comprises the amino acid sequence of SEQ ID NO: 170.

[0186] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the Fc1 comprises the amino acid sequence of SEQ ID NO: 169; and the Fc2 comprises the amino acid sequence of SEQ ID NO: 170.

[0187] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the Fc1 comprises the amino acid sequence of SEQ ID NO: 182 and the Fc2 comprises the amino acid sequence of SEQ ID NO: 183. Alternatively, vice versa, the Fc2 comprises the amino acid sequence of SEQ ID NO: 182 and the Fc1 comprises the amino acid sequence of SEQ ID NO: 183.

[0188] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the Fc1 comprises the amino acid sequence of SEQ ID NO: 182; and the Fc2 comprises the amino acid sequence of SEQ ID NO: 183.

[0189] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the antigen binding molecule comprises one antigen binding moiety that specifically binds to EGFR and one antigen binding moiety that specifically binds to MUC1.

[0190] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 is as described in any of the preceding items, wherein the antigen binding molecule comprises an antigen binding moiety that specifically binds to EGFR and an antigen binding moiety that specifically binds to MUC1, the antigen binding moiety that specifically binds to MUC1 is Fab, and the antigen binding moiety that specifically binds to EGFR is a replaced Fab that comprises a titin chain and an obscurin chain that can form a dimer; or the antigen binding moiety that specifically binds to EGFR is Fab, and the antigen binding moiety that specifically binds to MUC1 is a replaced Fab that comprises a titin chain and an obscurin chain that can form a dimer.

[0191] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 is as described in any of the preceding items, wherein the antigen binding molecule comprises an antigen binding moiety that specifically binds to EGFR and an antigen binding moiety that specifically binds to MUC1, and the antigen binding moiety that specifically binds to MUC1 is a Fab; the antigen binding moiety that specifically binds to EGFR is a replaced Fab, which comprises a titin chain and an obscurin chain that can form a dimer.

[0192] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the antigen binding molecule comprises a first chain having a structure represented by formula (a), a second chain having a structure represented by formula (b), a third chain having a structure represented by formula (c), and a fourth chain having a structure represented by formula (d),

[0193] Formula (a) [MUC1-VH]-[CH1]-[Fc1],

[0194] Formula (b) [MUC1-VL]-[CL],

[0195] Formula (c) [EGFR-VH]-[Linker 1]-[Titin]-[Fc2],

[0196] Formula (d): [EGFR-VL]-[Linker 2]-[Obscurin],

[0197] in:

[0198] The linker 1 and linker 2 are the same or different and are peptide linkers; or linker 1 or linker 2 does not exist;

[0199] The structures shown in formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus.

[0200] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and

[0201] a. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0202] b. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128 or 130, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or

[0203] c. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 133, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0204] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 is as described in any of the preceding items, wherein the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0205] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, 142, 144 or 147, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149.

[0206] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149.

[0207] In some embodiments, the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the linker 1 is a peptide linker known in the art, as long as the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker can be a flexible peptide having 1-50 or 3-20 amino acid residues. In some embodiments, the peptide linkers each independently have the structure L1-(GGGGS)t-L2, wherein L1 is a bond, A, G, GS, GGG, GGS, or GGGGS (SEQ ID NO: 168), t is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, L2 is a bond, G, GG, GGG, or GGGG (SEQ ID NO: 181), and the peptide linker is not a bond. In some embodiments, the linkers 1 and 2 are identical, and their amino acid sequences are as shown in SEQ ID NO: 168.

[0208] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the CH1 is the CH1 sequence of IgG. In some embodiments, the CH1 is the CH1 of IgG1. In some embodiments, the CH1 comprises the amino acid sequence of SEQ ID NO: 167.

[0209] In some embodiments, the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, wherein the CL is an antibody light chain constant region. In some embodiments, the antigen-binding molecule as described in any of the preceding items, wherein the CL is a kappa or lamada light chain constant region. In some embodiments, wherein the CL comprises the amino acid sequence of SEQ ID NO: 70.

[0210] In some embodiments, the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items is formatted as an asymmetric structure molecule comprising four chains, as shown in FIG5 .

[0211] In some embodiments, the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has an asymmetric structural molecule format comprising four chains, as shown in Figure 5; wherein the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: The amino acid sequence of NO:121.

[0212] In some embodiments, the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has an asymmetric structural molecule format comprising four chains, as shown in Figure 5; wherein the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149.

[0213] In some embodiments, the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 174, 172, 175, 176 or 177, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173; or the antigen-binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 178, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 179, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0214] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 174, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0215] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 172, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0216] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 175, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0217] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 176, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0218] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 177, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0219] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain comprising the amino acid sequence of SEQ ID NO: 178, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 179, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0220] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain as shown in SEQ ID NO: 171, a second chain as shown in SEQ ID NO: 74, a third chain as shown in SEQ ID NO: 174 and a fourth chain as shown in SEQ ID NO: 173.

[0221] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain as shown in SEQ ID NO: 171, a second chain as shown in SEQ ID NO: 74, a third chain as shown in SEQ ID NO: 172, and a fourth chain as shown in SEQ ID NO: 173.

[0222] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain as shown in SEQ ID NO: 171, a second chain as shown in SEQ ID NO: 74, a third chain as shown in SEQ ID NO: 175, and a fourth chain as shown in SEQ ID NO: 173.

[0223] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain as shown in SEQ ID NO: 171, a second chain as shown in SEQ ID NO: 74, a third chain as shown in SEQ ID NO: 176, and a fourth chain as shown in SEQ ID NO: 173.

[0224] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain as shown in SEQ ID NO: 171, a second chain as shown in SEQ ID NO: 74, a third chain as shown in SEQ ID NO: 177, and a fourth chain as shown in SEQ ID NO: 173.

[0225] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items has: a first chain as shown in SEQ ID NO: 178, a second chain as shown in SEQ ID NO: 74, a third chain as shown in SEQ ID NO: 179, and a fourth chain as shown in SEQ ID NO: 173.

[0226] On the other hand, the present disclosure provides an immunoconjugate comprising: an anti-MUC1 antibody or antigen-binding fragment thereof and an effector molecule as described in any of the preceding items, or an anti-EGFR antibody or antigen-binding fragment thereof and an effector molecule as described in any of the preceding items, or an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items and an effector molecule, wherein the effector molecule is conjugated to the anti-MUC1 antibody or antigen-binding fragment thereof, the anti-EGFR antibody or antigen-binding fragment thereof, or the antigen-binding molecule that specifically binds to EGFR and MUC1; preferably, the effector molecule is selected from an anti-tumor agent, an immunomodulator, a biological response modifier, a lectin, a cytotoxic drug, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.

[0227] In some embodiments, the effector molecule is a cytotoxic drug; preferably, the cytotoxic drug is an ixetine-type drug or an MMAE / MMAF-type drug.

[0228] In another aspect, the present disclosure provides an antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof:

[0229] Y is selected from -O-(CR a R b ) m -CR 1 R 2 -C(O)-, -O-CR 1 R 2 -(CR a R b ) m -、-O-CR 1 R 2 -、-NH-(CR a R b ) m -CR 1 R 2 -C(O)- or -S-(CR a R b ) m -CR 1 R 2 -C(O)-;

[0230] R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;

[0231] Or, R a and R b together with the carbon atom to which it is attached, form a cycloalkyl, heterocyclyl, aryl or heteroaryl group;

[0232] R 1 is selected from halogen, alkyl, haloalkyl, deuterated alkyl, hydroxy, alkoxy, cyano, amino, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl or heteroaryl;

[0233] R 2 is selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyl group, an alkoxy group, a cyano group, an amino group, a cycloalkyl group, a cycloalkylalkyl group, an alkoxyalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;

[0234] Or, R 1 and R 2 together with the carbon atom to which it is attached, form a cycloalkyl, heterocyclyl, aryl or heteroaryl group;

[0235] Or, R a and R 2 together with the carbon atom to which it is attached, form a cycloalkyl, heterocyclyl, aryl, or heteroaryl group;

[0236] m is 0, 1, 2, 3 or 4;

[0237] n is 1 to 10;

[0238] L is the joint unit;

[0239] Pc is the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, or the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, or the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items; preferably, Pc is the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items.

[0240] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof, wherein:

[0241] Y is -O-(CR a R b ) m -CR 1 R2 -C(O)-;

[0242] Among them, R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen and an alkyl group;

[0243] R 1 is cycloalkyl-alkyl or cycloalkyl;

[0244] R 2 is selected from the group consisting of a hydrogen atom, a haloalkyl group, and a cycloalkyl group;

[0245] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl group;

[0246] m is 0, 1, 2, 3 or 4;

[0247] n is 1 to 10;

[0248] L is the joint unit;

[0249] Pc is the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, or the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, or the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items; preferably, Pc is the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items.

[0250] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof, wherein:

[0251] Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-;

[0252] Among them, R a and R b are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, halogens and C 1-6 alkyl;

[0253] R 1 is a 3- to 6-membered cycloalkyl-C 1-6 Alkyl or 3- to 6-membered cycloalkyl;

[0254] R 2 Selected from hydrogen atoms, C 1-6 Haloalkyl and 3- to 6-membered cycloalkyl;

[0255] Or, R1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group;

[0256] m is 0, 1, 2, 3 or 4;

[0257] n is 1 to 10;

[0258] L is the joint unit;

[0259] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1, comprising an antigen-binding moiety that specifically binds to EGFR and an antigen-binding moiety that specifically binds to MUC1, wherein the antigen-binding moiety that specifically binds to EGFR comprises a heavy chain variable region EGFR-VH and a light chain variable region EGFR-VL, and the antigen-binding moiety that specifically binds to MUC1 comprises a heavy chain variable region MUC1-VH and a light chain variable region MUC1-VL; wherein:

[0260] the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121;

[0261] Preferably, the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149;

[0262] More preferably, the antigen-binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 174, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173; or a first chain comprising the amino acid sequence of SEQ ID NO: 178, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 179, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0263] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof, wherein:

[0264] Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-;

[0265] Among them, R a and R b are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, halogens and C 1-6 alkyl;

[0266] R 1 is a 3- to 6-membered cycloalkyl-C 1-6 Alkyl or 3- to 6-membered cycloalkyl;

[0267] R 2 Selected from hydrogen atoms, C 1-6 Haloalkyl and 3- to 6-membered cycloalkyl;

[0268] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group;

[0269] m is 0, 1, 2, 3 or 4;

[0270] n is 1 to 10;

[0271] L is the joint unit;

[0272] Pc is an anti-MUC1 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein:

[0273] the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 12, HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 15, LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 17;

[0274] Preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39;

[0275] More preferably, Pc is an anti-MUCl antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:71, and the light chain comprises the amino acid sequence of SEQ ID NO:72.

[0276] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof, wherein:

[0277] Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-;

[0278] Among them, R a and R b are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, halogens and C 1-6 alkyl;

[0279] R 1 is a 3- to 6-membered cycloalkyl-C 1-6 Alkyl or 3- to 6-membered cycloalkyl;

[0280] R 2 Selected from hydrogen atoms, C 1-6 Haloalkyl and 3- to 6-membered cycloalkyl;

[0281] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group;

[0282] m is 0, 1, 2, 3 or 4;

[0283] n is 1 to 10;

[0284] L is the joint unit;

[0285] Pc is an anti-EGFR antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein:

[0286] the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 116, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121;

[0287] Preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 138, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149;

[0288] More preferably, Pc is an anti-EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 153, and the light chain comprises the amino acid sequence of SEQ ID NO: 164. In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -,

[0289] Where: L 1 Selected from -(succinimide-3-yl-N)-WC(O)-, -CH2-C(O)-NR 3 -WC(O)- and -C(O)-WC(O)-, W is selected from alkylene and alkylene-cycloalkyl, wherein the alkylene or alkylene-cycloalkyl are each independently optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl;

[0290] L 2 Selected from-NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1C(O)- and chemical bonds, where p 1 is an integer from 1 to 20;

[0291] L 3 is a peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl;

[0292] L 4 Selected from-NR 5 (CR 6 R 7 ) t -、-C(O)NR 5 -、-C(O)NR 5 (CH2) t - and chemical bonds, where t is 1, 2, 3, 4, 5 or 6;

[0293] R 3 、R 4 and R 5 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a deuterated alkyl group, and a hydroxyalkyl group;

[0294] R 6 and R 7 are the same or different and are each independently selected from hydrogen, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl;

[0295] Preferably, wherein the linker unit-L 1 -L 2 -L 3 -L 4 -as follows:

[0296] L 1 for where s 1 is 2, 3, 4, 5, 6, 7, or 8;

[0297] L 2 is a chemical bond;

[0298] L 3 is a tetrapeptide residue; preferably, L 3 is the tetrapeptide residue represented by GGFG (SEQ ID NO: 180);

[0299] L 4 -NR 5 (CR 6 R7 )t-, where R 5 、R 6 or R 7 The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl, t is 1 or 2;

[0300] wherein the -L- 1 The end is connected to PC, L 4 Connect the Y end.

[0301] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof is a general formula (Pc-L a -YD) an antibody-drug conjugate or a pharmaceutically acceptable salt thereof:

[0302] in:

[0303] Pc is the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, or the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, or the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items; preferably, Pc is the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items;

[0304] m is 0, 1, 2, 3 or 4;

[0305] n is 1 to 10;

[0306] R 1 is cycloalkyl-alkyl or cycloalkyl;

[0307] R 2 is selected from the group consisting of a hydrogen atom, a haloalkyl group, and a cycloalkyl group;

[0308] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl group;

[0309] W is selected from alkylene and alkylene-cycloalkyl, wherein said alkylene and alkylene-cycloalkyl are each independently optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl;

[0310] L 2 Selected from-NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20;

[0311] L 3 is a peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl;

[0312] R 4 and R 5 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, and a hydroxyalkyl group;

[0313] R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group.

[0314] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof is a general formula (Pc-L a -YD) shown in the antibody - drug conjugate or a pharmaceutically acceptable salt thereof:

[0315] in:

[0316] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items;

[0317] m is 0, 1, 2, 3 or 4;

[0318] n is 1 to 10;

[0319] R 1 is a 3- to 6-membered cycloalkyl-C 1-6 Alkyl or 3- to 6-membered cycloalkyl;

[0320] R 2 Selected from hydrogen atoms, C 1-6 Haloalkyl and 3- to 6-membered cycloalkyl;

[0321] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group;

[0322] W is selected from C 1-6 Alkylene and C 1-6 Alkylene-3 to 6-membered cycloalkyl, wherein the C 1-6Alkylene and C 1-6 Alkylene-3 to 6 membered cycloalkyl groups are each independently optionally selected from halogen, hydroxy, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents of alkoxy and 3- to 6-membered cycloalkyl;

[0323] L 2 Selected from-NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20;

[0324] L 3 The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and is optionally selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents selected from alkoxy and 3- to 6-membered cycloalkyl;

[0325] R 4 and R 5 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl and C 1-6 hydroxyalkyl;

[0326] R 6 and R 7 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl and C 1-6 Hydroxyalkyl.

[0327] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof is a general formula (Pc-L a -YD) an antibody-drug conjugate or a pharmaceutically acceptable salt thereof:

[0328] in,

[0329] Pc is an anti-MUC1 antibody or an antigen-binding fragment thereof as described in any of the preceding items;

[0330] m is 0, 1, 2, 3 or 4;

[0331] n is 1 to 10;

[0332] R 1 is a 3- to 6-membered cycloalkyl-C 1-6 Alkyl or 3- to 6-membered cycloalkyl;

[0333] R 2 Selected from hydrogen atoms, C 1-6 Haloalkyl and 3- to 6-membered cycloalkyl;

[0334] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group;

[0335] W is selected from C 1-6 Alkylene and C 1-6 Alkylene-3 to 6-membered cycloalkyl, wherein the C 1-6 Alkylene and C 1-6 Alkylene-3 to 6 membered cycloalkyl groups are each independently optionally selected from halogen, hydroxy, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents of alkoxy and 3- to 6-membered cycloalkyl;

[0336] L 2 Selected from-NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20;

[0337] L 3 The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and is optionally selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6Deuterated alkyl, C 1-6 substituted by one or more substituents selected from alkoxy and 3- to 6-membered cycloalkyl;

[0338] R 4 and R 5 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl and C 1-6 hydroxyalkyl;

[0339] R 6 and R 7 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl and C 1-6 Hydroxyalkyl.

[0340] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof is a general formula (Pc-L a -YD) an antibody-drug conjugate or a pharmaceutically acceptable salt thereof:

[0341] in,

[0342] Pc is the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items;

[0343] m is 0, 1, 2, 3 or 4;

[0344] n is 1 to 10;

[0345] R 1 is a 3- to 6-membered cycloalkyl-C 1-6 Alkyl or 3- to 6-membered cycloalkyl;

[0346] R 2 Selected from hydrogen atoms, C 1-6 Haloalkyl and 3- to 6-membered cycloalkyl;

[0347] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group;

[0348] W is selected from C 1-6 Alkylene and C 1-6 Alkylene-3 to 6-membered cycloalkyl, wherein the C 1-6 Alkylene and C 1-6 Alkylene-3 to 6 membered cycloalkyl groups are each independently optionally selected from halogen, hydroxy, cyano, amino, C 1-6Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents of alkoxy and 3- to 6-membered cycloalkyl;

[0349] L 2 Selected from-NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20;

[0350] L 3 The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and is optionally selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents selected from alkoxy and 3- to 6-membered cycloalkyl;

[0351] R 4 and R 5 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl and C 1-6 hydroxyalkyl;

[0352] R 6 and R 7 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl and C 1-6 Hydroxyalkyl.

[0353] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) or a pharmaceutically acceptable salt thereof, wherein m is 0.

[0354] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein R1 is a 3- to 6-membered cycloalkyl group; preferably, R 1 It is cyclopropyl.

[0355] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein R 2 A hydrogen atom.

[0356] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group.

[0357] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) shown in the antibody - drug conjugate or a pharmaceutically acceptable salt thereof, wherein W is selected from C 1-6 Alkylene.

[0358] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein L 2 For chemical bonds.

[0359] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein L 3 The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and is optionally selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents of alkoxy and 3 to 6-membered cycloalkyl; preferably, L 3 is a tetrapeptide residue; more preferably, L 3 It is a tetrapeptide residue represented by GGFG (SEQ ID NO: 180).

[0360] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a-YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein R 5 A hydrogen atom.

[0361] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein R 6 and R 7 All are hydrogen atoms.

[0362] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) or a pharmaceutically acceptable salt thereof, which is an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:

[0363] in:

[0364] n is 1 to 8;

[0365] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items.

[0366] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) or a pharmaceutically acceptable salt thereof, which is an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:

[0367] in:

[0368] n is 1 to 8;

[0369] Pc is the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items.

[0370] In some embodiments, the general formula (Pc-LYD) or the general formula (Pc-L a -YD) or a pharmaceutically acceptable salt thereof, which is an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:

[0371] in:

[0372] n is 1 to 8;

[0373] Pc is the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items.

[0374] On the other hand, the present disclosure provides a method for preparing a a -YD) or a pharmaceutically acceptable salt thereof, comprising the following steps:

[0375] After Pc reduction, with the general formula (L a -YD) or its salt undergoes coupling reaction to obtain the general formula (Pc-L a -YD) an antibody-drug conjugate or a pharmaceutically acceptable salt thereof;

[0376] in:

[0377] Pc is the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, or the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, or the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items; preferably, Pc is the antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items; W, L 2 , L 3 、R 1 、R 2 、R 5 to R 7 , m and n are as defined in the previous item.

[0378] In some embodiments, n is 0 to 10 (including decimals or integers, the same below).

[0379] In some embodiments, n is 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, calculated as an average.

[0380] In some embodiments, n is 1 to 8; preferably, n is 2 to 8; more preferably, n is 4 to 8; most preferably, n is 4 to 6.

[0381] In another aspect, the present disclosure provides a compound represented by the general formula (Pc-M') or a pharmaceutically acceptable salt thereof:

[0382] in:

[0383] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1, comprising an antigen-binding moiety that specifically binds to EGFR and an antigen-binding moiety that specifically binds to MUC1, wherein the antigen-binding moiety that specifically binds to EGFR comprises a heavy chain variable region EGFR-VH and a light chain variable region EGFR-VL, and the antigen-binding moiety that specifically binds to MUC1 comprises a heavy chain variable region MUC1-VH and a light chain variable region MUC1-VL; wherein:

[0384] the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121;

[0385] Preferably, the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149;

[0386] More preferably, the antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 174, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173; or a first chain comprising the amino acid sequence of SEQ ID NO: 178, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 179, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173;

[0387] W' is selected from alkylene and alkylene-cycloalkyl, wherein said alkylene and alkylene-cycloalkyl are each independently optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl;

[0388] L 2a Selected from-NR 4a (CH2CH2O)p 2CH2CH2C(O)-、-NR 4a (CH2CH2O)p 2 CH2C(O)-、-S(CH2)p 2 C(O)- and chemical bonds, where p 2 is an integer from 1 to 20;

[0389] L 3a is a peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl;

[0390] R 4a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, and a hydroxyalkyl group;

[0391] R c 、R d 、R e and R f are the same or different, and at least one of them is selected from halogen, alkenyl, alkyl and cycloalkyl, and the rest are hydrogen atoms;

[0392] or R c 、R d 、R e and R f Any two of them together with the carbon atom to which they are attached form a cycloalkyl group, and the remaining two can be selected from hydrogen atoms, alkyl groups and cycloalkyl groups;

[0393] R 8 、R 10 、R 12 and R 14 to R 17 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;

[0394] R 9 、R 11 and R 13 are the same or different and are each independently selected from hydrogen, halogen, hydroxy, cyano, amino, alkyl, haloalkyl, hydroxyalkyl, alkoxy, cycloalkyl, heterocyclic, aryl and heteroaryl;

[0395] R 18 is an aryl or heteroaryl group, wherein the aryl or heteroaryl group is optionally further substituted by a substituent selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, cycloalkyl, heterocyclic, aryl and heteroaryl groups;

[0396] s is 1 to 10.

[0397] In some embodiments, the compound represented by the general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein W' is selected from C 1-6 Alkylene.

[0398] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein L 2a For chemical bonds.

[0399] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein L 3a The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and is optionally selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents of alkoxy and 3 to 6-membered cycloalkyl; preferably, L 3 is a tetrapeptide residue; more preferably, L 3 It is a tetrapeptide residue represented by GGFG (SEQ ID NO: 180).

[0400] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein R c and R d One, R e and R f One of them together with the carbon atom to which they are attached forms a 3-6 membered cycloalkyl group, and the remaining two are hydrogen atoms; preferably, R c and R d One, R e and R f One of them together with the carbon atom to which they are attached forms a cyclopropyl group, and the remaining two are hydrogen atoms.

[0401] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein R 8 、R 10 、R 12 and R 14 to R 17 The same or different, and each independently a hydrogen atom or a C 1-6 alkyl.

[0402] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein R 8 、R 12 、R 14 and R 15 The same or different, and each independently a hydrogen atom or a C 1-6 alkyl.

[0403] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein R 10 and R 16 All are hydrogen atoms.

[0404] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein R 17 A hydrogen atom.

[0405] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein R 9 、R 11 and R 13 The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl; preferably, R 9 、R 11 and R 13 The same or different, and each independently is C 1-6 alkyl.

[0406] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein R 18 is a 6- to 10-membered aryl group, wherein the 6- to 10-membered aryl group is optionally further selected from hydrogen atoms, halogens, hydroxyl groups, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 substituted by an alkoxy substituent; preferably, R 18 is phenyl, wherein the phenyl group is optionally further selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 More preferably, R 18 is phenyl, which is optionally further substituted by halogen.

[0407] In some embodiments, the compound represented by the aforementioned general formula (Pc-M') or a pharmaceutically acceptable salt thereof, wherein:

[0408] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items;

[0409] W' is selected from C 1-6 alkylene;

[0410] L 2a is a chemical bond;

[0411] L 3a The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and is optionally selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents selected from alkoxy and 3- to 6-membered cycloalkyl;

[0412] R c and R d One, R e and R f One of them together with the carbon atom to which they are attached forms a 3-6 membered cycloalkyl group, and the remaining two are optionally selected from hydrogen atoms, C 1-6 Alkyl and 3-6 membered cycloalkyl;

[0413] R 8 、R 10 、R 12 and R 14 to R 17 The same or different, and each independently a hydrogen atom or a C 1-6 alkyl;

[0414] R 9 、R 11 and R 13 The same or different, and each independently a hydrogen atom or a C 1-6 alkyl;

[0415] R 18 is a 6- to 10-membered aryl group, wherein the 6- to 10-membered aryl group is optionally further selected from hydrogen atoms, halogens, hydroxyl groups, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 substituted by an alkoxy substituent;

[0416] s is 1 to 10.

[0417] In some embodiments, the compound represented by the aforementioned general formula (PC-M') or a pharmaceutically acceptable salt thereof, wherein:

[0418] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items;

[0419] W' is selected from C 1-6 alkylene;

[0420] L 2a is a chemical bond;

[0421] L 3a The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and is optionally selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents selected from alkoxy and 3- to 6-membered cycloalkyl;

[0422] R c and R d One, R e and R f One of them together with the carbon atom to which they are attached forms a cyclopropyl group, and the remaining two are hydrogen atoms;

[0423] R 8 、R 10 、R 12 and R 14 to R 17 The same or different, and each independently a hydrogen atom or a C 1-6 alkyl;

[0424] R 9 、R 11 and R 13 The same or different, and each independently a hydrogen atom or a C 1-6 alkyl;

[0425] R 18 is a 6- to 10-membered aryl group, wherein the 6- to 10-membered aryl group is optionally further selected from hydrogen atoms, halogens, hydroxyl groups, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 substituted by an alkoxy substituent;

[0426] s is 4 to 8.

[0427] In some embodiments, the compound represented by the general formula (Pc-M') or a pharmaceutically acceptable salt thereof as described above is a compound represented by the general formula (Pc-M) or a pharmaceutically acceptable salt thereof, wherein:

[0428] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items;

[0429] s is 4 to 6.

[0430] In another aspect, the present disclosure provides a method for preparing an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as represented by the general formula (Pc-M'), comprising the following steps:

[0431] After Pc is reduced, it undergoes a coupling reaction with compound M' or a salt thereof to obtain an antibody-drug conjugate represented by the general formula (Pc-M') or a pharmaceutically acceptable salt thereof;

[0432] in:

[0433] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items;

[0434] W'、L 2a , L 3a 、R 8 to R 18 、R c 、R d 、R e 、R f and s are as defined in the preceding item.

[0435] In some embodiments, s is 0 to 10 (including decimals or integers, the same below).

[0436] In some embodiments, s is 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 calculated as an average.

[0437] In some embodiments, s is 1 to 8; preferably, s is 2 to 8; more preferably, s is 4 to 8; most preferably, s is 4 to 6.

[0438] On the other hand, the present disclosure provides a pharmaceutical composition comprising an anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, an anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any of the preceding items, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0439] In some embodiments, the present disclosure provides a pharmaceutical composition comprising the anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0440] In some embodiments, the present disclosure provides a pharmaceutical composition comprising the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0441] In some embodiments, the present disclosure provides a pharmaceutical composition comprising an antigen binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0442] In some embodiments, the present disclosure provides a pharmaceutical composition comprising the anti-MUC1 antibody or antigen-binding fragment thereof drug conjugate or a pharmaceutically acceptable salt thereof as described in any of the preceding items, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0443] In some embodiments, the present disclosure provides a pharmaceutical composition comprising the anti-EGFR antibody or antigen-binding fragment thereof drug conjugate or a pharmaceutically acceptable salt thereof as described in any of the preceding items, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0444] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a drug conjugate of an antigen-binding molecule that specifically binds to EGFR and MUC1 (i.e., an EGFR-MUC1 bispecific ADC) as described in any of the preceding items, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0445] In another aspect, the present disclosure provides an isolated nucleic acid encoding the anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items or the anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items.

[0446] In some embodiments, the present disclosure provides an isolated nucleic acid encoding an anti-MUCl antibody or antigen-binding fragment thereof as described in any of the preceding items.

[0447] In some embodiments, the present disclosure provides an isolated nucleic acid encoding an anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items.

[0448] In another aspect, the present disclosure provides a host cell comprising the isolated nucleic acid as described in any one of the above items.

[0449] In another aspect, the present disclosure provides a method for preventing or treating a disease, comprising administering to a subject a preventively or therapeutically effective amount of an anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, an anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, an antibody-drug conjugate as described in any of the preceding items, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0450] In some embodiments, the method for preventing or treating a disease as described above comprises administering to a subject a preventively or therapeutically effective amount of the anti-MUC1 antibody or antigen-binding fragment thereof or pharmaceutical composition thereof as described in any one of the above items.

[0451] In some embodiments, the method for preventing or treating a disease as described above comprises administering to a subject a preventively or therapeutically effective amount of an anti-EGFR antibody or antigen-binding fragment thereof or a pharmaceutical composition thereof as described in any one of the above.

[0452] In some embodiments, the method for preventing or treating a disease as described above comprises administering to a subject a preventively or therapeutically effective amount of an antigen binding molecule that specifically binds to EGFR and MUC1 as described in any one of the above items, or a pharmaceutical composition thereof.

[0453] In some embodiments, the method for preventing or treating a disease as described above comprises administering to a subject a preventively or therapeutically effective amount of a drug conjugate of an anti-MUC1 antibody or antigen-binding fragment thereof as described above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0454] In some embodiments, the method for preventing or treating a disease as described above comprises administering to a subject a preventively or therapeutically effective amount of a drug conjugate of an anti-EGFR antibody or antigen-binding fragment thereof as described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0455] In some embodiments, the method for preventing or treating a disease as described above comprises administering to a subject a preventively or therapeutically effective amount of a drug conjugate of an antigen-binding molecule that specifically binds to EGFR and MUC1 (i.e., an EGFR-MUC1 dual-antibody ADC) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as described above.

[0456] On the other hand, the present disclosure provides a use in preparing a medicament for preventing or treating a disease, comprising administering to a subject a preventively or therapeutically effective amount of an anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, an anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, an antibody-drug conjugate as described in any of the preceding items, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0457] In some embodiments, the use as described above in preparing a medicament for preventing or treating a disease comprises administering to a subject a preventively or therapeutically effective amount of the anti-MUC1 antibody or antigen-binding fragment thereof or pharmaceutical composition thereof as described above.

[0458] In some embodiments, the use as described above in preparing a medicament for preventing or treating a disease comprises administering to a subject a preventively or therapeutically effective amount of an anti-EGFR antibody or antigen-binding fragment thereof or a pharmaceutical composition thereof as described above.

[0459] In some embodiments, the use as described above in preparing a medicament for preventing or treating a disease comprises administering to a subject a preventively or therapeutically effective amount of an antigen binding molecule that specifically binds to EGFR and MUC1 as described above, or a pharmaceutical composition thereof.

[0460] In some embodiments, the use as described above in preparing a medicament for preventing or treating a disease comprises administering to a subject a preventively or therapeutically effective amount of a drug conjugate of an anti-MUC1 antibody or antigen-binding fragment thereof as described above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0461] In some embodiments, the use as described above in the preparation of a medicament for preventing or treating a disease comprises administering to a subject a preventively or therapeutically effective amount of a drug conjugate of an anti-EGFR antibody or antigen-binding fragment thereof as described above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0462] In some embodiments, the use as described above in the preparation of a medicament for preventing or treating a disease comprises administering to a subject a preventively or therapeutically effective amount of a drug conjugate of an antigen-binding molecule that specifically binds to EGFR and MUC1 (i.e., EGFR-MUC1 dual-antibody ADC) or a pharmaceutically acceptable salt thereof as described above.

[0463] In another aspect, the present disclosure provides an anti-MUC1 antibody or antigen-binding fragment thereof as described in any of the preceding items, an anti-EGFR antibody or antigen-binding fragment thereof as described in any of the preceding items, an antigen-binding molecule that specifically binds to EGFR and MUC1 as described in any of the preceding items, an antibody-drug conjugate as described in any of the preceding items, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use as a medicament. In some embodiments, the medicament is used to prevent or treat a disease.

[0464] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof or pharmaceutical composition thereof as described above is used as a medicament. In some embodiments, the medicament is used for preventing or treating a disease.

[0465] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof or pharmaceutical composition thereof as described above is used as a medicament. In some embodiments, the medicament is used to prevent or treat a disease.

[0466] In some embodiments, the antigen binding molecule that specifically binds to EGFR and MUC1 or a pharmaceutical composition thereof as described above is used as a medicament. In some embodiments, the medicament is used to prevent or treat a disease.

[0467] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof drug conjugate or pharmaceutically acceptable salt thereof or pharmaceutical composition thereof as described above is used as a medicament. In some embodiments, the medicament is used for preventing or treating a disease.

[0468] In some embodiments, the anti-EGFR antibody or antigen-binding fragment thereof drug conjugate as described above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is used as a medicament. In some embodiments, the medicament is used to prevent or treat a disease.

[0469] In some embodiments, the drug conjugate of the antigen-binding molecule that specifically binds to EGFR and MUC1 (i.e., EGFR-MUC1 dual-antibody ADC) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof as described above is used as a drug. In some embodiments, the drug is used to prevent or treat a disease.

[0470] In some embodiments, the disease as described in any of the above items is a tumor; in some embodiments, the disease is selected from astrocytoma (e.g., anaplastic astrocytoma), glioblastoma, bladder cancer, bone cancer, brain cancer, breast cancer (e.g., breast cancer characterized by BRCA1 and / or BRCA2 mutations), cervical cancer, colorectal cancer (e.g., colon cancer and rectal cancer), fallopian tube cancer, gallbladder cancer, gastric cancer, head and neck cancer, idiopathic myelofibrosis, kidney cancer (e.g., renal cell carcinoma, renal rhabdoid tumor and Wilms' tumor), leukemia, liver cancer (e.g., hepatocellular carcinoma), esophageal cancer (also known as "esophageal cancer", such as esophageal squamous cell carcinoma), lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, polyangiitis, leukemia, leukemia, hepatocellular carcinoma, esophageal cancer (also known as "esophageal cancer", such as esophageal squamous cell carcinoma), lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, polyangiitis, leukemia ... In some embodiments, the cancer is selected from the group consisting of: primary myeloma, neuroblastoma, oligodendroglioma, ovarian cancer, peritoneal tumor, pancreatic cancer, polycythemia vera, primary neuroectodermal tumor, prostate cancer, retinoblastoma, sarcoma (e.g., chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, synovial sarcoma, and soft tissue sarcoma), squamous cell carcinoma (e.g., cutaneous squamous cell carcinoma), thyroid cancer, endometrial cancer, vestibular schwannoma, blastoma, vulvar cancer, thymoma, testicular cancer, bile duct cancer, pheochromocytoma, paraganglioma, and adenoid cystic carcinoma; in some embodiments, the cancer is selected from the group consisting of lung cancer, head and neck cancer, esophageal cancer, breast cancer, pancreatic cancer, prostate cancer, thyroid cancer, gastric cancer, ovarian cancer, colorectal cancer, liver cancer, gallbladder cancer, kidney cancer, cervical cancer, and bladder cancer. In some embodiments, the cancer is lung cancer; preferably, non-small cell lung cancer.

[0471] The ordinal numbers "first", "second", "third", "1", "2", "3", etc. (such as "first subunit", "Fc2", "third chain", "linker 2") in this disclosure are only used to distinguish different features, elements, components or steps, and are not intended to limit the quantity, order or level. BRIEF DESCRIPTION OF THE DRAWINGS

[0472] Figures 1 and 2 show the results of in vitro internalization experiments of chimeric antibodies on T47D cells;

[0473] Figures 3A to 3E show the experimental results of FACS-based determination of the affinity of chimeric antibodies and humanized antibodies for HCC827-human-MUC1-C cells;

[0474] Figures 3F to 3H show the experimental results of FACS-based determination of the affinity of chimeric antibodies and humanized antibodies for CHOK1-human-MUC1-C cells;

[0475] Figures 3I to 3P show the experimental results of FACS-based determination of the affinity of chimeric antibodies and humanized antibodies for T47D (MUC1 high expression, EGFR low expression) cells;

[0476] Figures 4A to 4F show the results of in vitro internalization experiments of MUCl-C humanized antibodies on T47D cells;

[0477] Figure 5 shows a schematic diagram of the EGFR-MUC1 dual antibody molecular format;

[0478] Figures 6A and 6B show the experimental results of the killing activity of EGFR-MUC1 dual-antibody ADC (coupled with M toxin) with different mutations against tumor cell lines HCC827 (EGFR high expression, MUC1 low expression) and HCC70 (EGFR medium expression, MUC1 medium expression);

[0479] Figure 7A shows the curves of tumor volume changes in different groups over the study days in the HCC827 CDX mouse model;

[0480] Figure 7B shows the curves of body weight changes of mice in different groups over the study days in the HCC827 CDX mouse model;

[0481] Figure 8A shows the curves of tumor volume changes in different groups over the study days in the HPAC CDX mouse model;

[0482] FIG8B shows the curves of body weight changes of mice in different groups over the study days in the HPAC CDX mouse model. DETAILED DESCRIPTION

[0483] the term

[0484] In order to make the present disclosure more easily understood, certain technical and scientific terms are described below. Unless otherwise specifically defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0485] As used in the specification and claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0486] Unless the context clearly requires otherwise, in the patent specification and claims, the words "comprising," "having," "including," and the like should be construed in the sense of "including but not limited to," rather than in an exclusive or exhaustive sense.

[0487] The term "cytokine" is a general term for proteins released by one cell population that act as intercellular mediators on other cells. Examples of such cytokines include lymphokines, monokines, chemokines, and traditional polypeptide hormones. Exemplary cytokines include mIL-2, IFNγ, TNFα, CCL-2, and IL-6.

[0488] The term "and / or" is intended to include both "and" and "or". For example, the phrase "A, B and / or C" is intended to include each of the following: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0489] The three letter and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).

[0490] The term "MUCl" refers to the full-length MUCl protein, and human MUCl has the amino acid sequence of SEQ ID NO: 2. Amino acid sequences of MUCl molecules from non-human species (eg, mouse, monkey, rabbit, dog, pig, etc.) are available from public sources.

[0491] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., an alpha carbon bound to a hydrogen, a carboxyl group, an amino group, and an R group), such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but function in a manner similar to naturally occurring amino acids.

[0492] The term "amino acid mutation" includes amino acid substitutions (also known as amino acid replacements), deletions, insertions, and modifications. Any combination of substitutions, deletions, insertions, and modifications can be performed to achieve the final construct, as long as the final construct possesses the desired properties, such as reduced binding to Fc receptors. Amino acid sequence deletions and insertions include deletions and insertions at the amino and / or carboxyl termini of the polypeptide chain. Specific amino acid mutations can be amino acid substitutions. In one embodiment, the amino acid mutation is a non-conservative amino acid substitution, i.e., replacing one amino acid with another amino acid having different structural and / or chemical properties. Amino acid substitutions include replacement with non-naturally occurring amino acids or with derivatives of the 20 natural amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, and the like. It is expected that methods other than genetic engineering to alter amino acid side chain groups, such as chemical modification, may also be useful. Various names may be used herein to refer to the same amino acid mutation. Herein, the amino acid residue at a specific position can be represented by position + amino acid residue, for example, 82aR means that the amino acid residue at position 82a is R. S82aR means that the amino acid residue at position 82a (also known as 82A) has mutated from S to R.

[0493] The term "antigen binding molecule" is used in the broadest sense to encompass various molecules that specifically bind to antigens, including but not limited to antibodies, other polypeptides with antigen binding activity, and antibody fusion proteins formed by fusion of the two, as long as they exhibit the desired antigen binding activity. The antigen binding molecules herein comprise a variable region (VH) and a variable region (VL), which together constitute an antigen binding domain. Exemplary, the antigen binding molecules herein are bispecific antigen binding molecules (e.g., bispecific antibodies).

[0494] The term "antibody" is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies; monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antigen-binding portions), as long as they exhibit the desired antigen-binding activity. For example, a natural IgG antibody is a heterotetrameric glycoprotein of approximately 150,000 daltons, consisting of two light chains and two heavy chains bound by disulfide bonds. From N to C-terminus, each heavy chain has a variable region (VH), also known as a variable heavy domain, a heavy chain variable region, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N to C-terminus, each light chain has a variable region (VL), also known as a variable light domain, or a light chain variable domain, followed by a constant light domain (light chain constant region, CL).

[0495] The term "bispecific antibody" refers to an antibody (including an antibody or its antigen-binding fragment, such as a single-chain antibody) that can specifically bind to two different antigens or at least two different antigenic epitopes of the same antigen. The prior art has disclosed bispecific antibodies of various structures. Based on the integrity of the IgG molecule, they can be divided into IgG-like bispecific antibodies and antibody fragment-type bispecific antibodies. Based on the number of antigen-binding regions, they can be divided into bispecific antibodies with different valencies, such as bispecific antibodies with different valencies. Based on whether the structure is symmetrical, they can be divided into bispecific antibodies with different symmetric structures and bispecific antibodies with different asymmetric structures. Among them, antibody fragment-type bispecific antibodies, such as Fab fragments lacking Fc fragments, are formed by combining two or more Fab fragments into one molecule. They have low immunogenicity, small molecular weight, and high tumor tissue penetration. Typical antibody structures of this type include F(ab)2, scFv-Fab, and (scFv)2-Fab; IgG-like bispecific antibodies (for example, with Fc fragments) have a relatively large molecular weight. The Fc fragment helps purify the antibody and improve its solubility and stability. The Fc part may also bind to the receptor FcRn to increase the antibody serum half-life.

[0496] "Native antibodies" refer to naturally occurring immunoglobulin molecules. For example, natural IgG antibodies are heterotetrameric glycoproteins of approximately 150,000 daltons, consisting of two identical light chains and two identical heavy chains bound by disulfide bonds. From N to C-terminus, each heavy chain has a variable region (VH), also known as a variable heavy domain, a heavy chain variable region, followed by a heavy chain constant region, and the natural IgG heavy chain constant region typically contains three constant domains (CH1, CH2, and CH3). Similarly, from N to C-terminus, each light chain has a variable region (VL), also known as a variable light domain, or a light chain variable domain, followed by a constant light domain (light chain constant region, CL). The terms "full-length antibody," "complete antibody," and "whole antibody" are used interchangeably herein and refer to antibodies having a structure substantially similar to that of a natural antibody structure or having a heavy chain with an Fc region as defined herein. A natural complete antibody light chain comprises a light chain variable region VL and a constant region CL, wherein VL is located at the amino terminus of the light chain, and the light chain constant region comprises a kappa chain and a lambda chain; a heavy chain comprises a variable region VH and constant regions (CH1, CH2, and CH3), wherein VH is located at the amino terminus of the heavy chain, and the constant region is at the carboxyl terminus, with CH3 being closest to the carboxyl terminus of the polypeptide. The heavy chain may belong to any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM, and IgE.

[0497] The term "variable region" or "variable domain" of an antibody refers to the domain of an antibody heavy or light chain involved in antigen binding. Herein, the heavy chain variable region (VH) and light chain variable region (VL) of an antibody each comprise four conserved framework regions (FRs) and three complementarity determining regions (CDRs). The term "complementarity determining region" or "CDR" refers to the region within the variable domain that primarily contributes to antigen binding; "framework" or "FR" refers to the variable domain residues excluding the CDR residues. The VH comprises three CDR regions: HCDR1, HCDR2, and HCDR3; the VL comprises three CDR regions: LCDR1, LCDR2, and LCDR3. Each VH and VL is composed of three CDRs and four FRs, arranged from the amino terminus (also called the N-terminus) to the carboxyl terminus (also called the C-terminus), in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0498] The amino acid sequence boundaries of CDRs can be determined by various well-known schemes, for example: "Kabat" numbering convention (see Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD), "Chothia" numbering convention, "ABM" numbering convention, "contact" numbering convention (see Martin, ACR. Protein Sequence and Structure Analysis of Antibody Variable Domains [J]. 2001) and ImMunoGenTics (IMGT) numbering convention (Lefranc, MP et al., Dev. Comp. Immunol., 27, 55-77 (2003); Front Immunol. 2018 Oct 16; 9: 2278), etc. The correspondence between various numbering systems is well known to those skilled in the art, and is exemplified as shown in Table 1 below.

[0499] Table 1. Relationships between CDR numbering systems

[0500] Unless otherwise indicated, the variable regions and CDRs in the disclosed embodiments are all subject to the "Kabat" numbering convention. Although in specific embodiments, a numbering system (such as Kabat) is used to define amino acid residues, corresponding technical solutions using other numbering systems will be considered equivalent technical solutions.

[0501] The term "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fd, Fv, Fab, dsFv, dAb, Fab', Fab'-SH, F(ab')2, single-domain antibodies, single-chain Fab (scFab), diabodies, linear antibodies, single-chain antibodies (e.g., scFv); and multispecific antibodies formed from antibody fragments.

[0502] The term "Fc region" or "fragment crystallizable region" is used to define the C-terminal region of the antibody heavy chain, including native Fc regions and reconstructed Fc regions. In some embodiments, the Fc region comprises two identical or different subunits. In some embodiments, the Fc region of a human IgG heavy chain is defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. Suitable Fc regions for the antibodies described herein include the Fc regions of human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4. In some embodiments, the boundaries of the Fc region can also vary, such as by deleting the C-terminal lysine in the Fc region (residue 447 according to the EU numbering system) or by deleting the C-terminal glycine and lysine in the Fc region (residues 446 and 447 according to the EU numbering system). Unless otherwise indicated, the numbering convention for the Fc region is the EU numbering system, also known as the EU index.

[0503] The term "chimeric" refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0504] The term "humanized" antibody is an antibody that retains the reactivity of a non-human antibody while having lower immunogenicity in humans. For example, humanization can be achieved by retaining the non-human CDR regions and replacing the rest of the antibody with their human counterparts (i.e., the constant region and the framework region portion of the variable region).

[0505] The terms "human antibody," "humanized antibody," "fully human antibody," and "completely human antibody" are used interchangeably to refer to antibodies whose variable and constant regions are human sequences. The term encompasses antibodies that are derived from human genes but have altered sequences, for example, to reduce potential immunogenicity, increase affinity, or eliminate cysteines or glycosylation sites that may cause undesirable folding. The term encompasses antibodies that are recombinantly produced in non-human cells (which may confer glycosylation that is not characteristic of human cells). The term also encompasses antibodies that have been bred in transgenic mice containing some or all human immunoglobulin heavy and light chain loci. The meaning of human antibody specifically excludes humanized antibodies that comprise non-human antigen-binding residues.

[0506] The term "affinity" refers to the overall strength of the non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding ligand (e.g., an antigen). Unless otherwise indicated, as used herein, binding "affinity" refers to internal binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its ligand Y can generally be represented by a dissociation constant (KD). Affinity can be measured by conventional methods known in the art, including those described herein.

[0507] As used herein, the term "kassoc" or "ka" refers to the association rate of a specific antibody-antigen interaction, and the term "kdis" or "kd" refers to the dissociation rate of a specific antibody-antigen interaction. The term "KD" refers to the dissociation constant, which is obtained from the ratio of kd to ka (i.e., kd / ka) and is expressed as molar concentration (M). The KD value of an antibody can be measured using methods well known in the art. For example, a biosensor system such as a system measuring surface plasmon resonance (e.g., Biacore) is used, or affinity in a solution is measured by solution equilibrium titration (SET).

[0508] The term "surface plasmon resonance" refers to an optical phenomenon that allows analysis of real-time interactions by detecting changes in protein concentration within a biosensor matrix, for example, using a BIAcore™ system (Biacore LifeSciences division of GE Healthcare, Piscataway, NJ).

[0509] The term "effector function" refers to those biological activities attributable to the Fc region of an antibody (either a native sequence Fc region or an amino acid sequence mutated Fc region) and varies with the antibody isotype. Examples of antibody effector functions include, but are not limited to, C1q binding and complement-dependent cytotoxicity, Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.

[0510] The term "monoclonal antibody" refers to a group of substantially homogeneous antibodies, i.e., the amino acid sequences of the antibody molecules contained in the group are identical, except for the natural mutations that may be present in small amounts. In contrast, polyclonal antibody preparations are typically comprised of a variety of different antibodies with different amino acid sequences in their variable domains, which are typically specific for different epitopes. "Monoclonal" represents the characteristic of an antibody obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring the production of antibodies by any ad hoc method. In some embodiments, the antibody provided by the present disclosure is a monoclonal antibody.

[0511] The term "antigen" refers to a molecule or portion of a molecule that can be selectively recognized or bound by an antigen binding molecule (including, for example, an antibody). An antigen may have one or more epitopes that can interact with different antigen binding molecules (e.g., antibodies).

[0512] The term "epitope" refers to an area or region on an antigen that is capable of specific binding to an antibody or antigen-binding fragment thereof. An epitope can be formed by a continuous string of amino acids (linear epitope) or comprise non-contiguous amino acids (conformational epitope), for example, brought into spatial proximity by folding of the antigen (i.e., by tertiary folding of the antigen in a proteinaceous manner). Conformational epitopes differ from linear epitopes in that antibody binding to a conformational epitope is lost in the presence of denaturing solvents. An epitope comprises at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation. Screening for antibodies that bind to a specific epitope (i.e., those that bind to the same epitope) can be performed using routine methods in the art, such as, but not limited to, alanine scanning, peptide blotting, peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of the antigen (see Prot. Sci. 9 (2000) 487-496), and cross-blocking.

[0513] The terms "capable of specific binding", "specific binding" or "binding" refer to an antibody that is able to bind to an antigen or an epitope of the antigen with a higher affinity than to other antigens or epitopes. -7 M or less (e.g., about 1×10 -8 M, 1×10 -9 M, 1×10 -10 M, 1×10 -11 In some embodiments, the antibody binds to the antigen with an equilibrium dissociation constant (KD) of 10% or less (e.g., 1%) of the KD of the antibody binding to a nonspecific antigen (e.g., BSA, casein). KD can be measured using known methods, such as by However, an antibody that specifically binds to an antigen or an epitope thereof does not exclude cross-reactivity to other related antigens, for example, to corresponding antigens from other species (homologous), such as humans or monkeys, for example, Macaca fascicularis (cynomolgus, cyno), chimpanzee (Pan troglodytes) (chimpanzee, chimp) or marmoset (Callithrix jacchus (common marmoset, marmoset).

[0514] The term "antigen binding moiety" refers to a polypeptide molecule that specifically binds to an antigen of interest or an epitope thereof. Specific antigen binding moieties include the antigen binding domain of an antibody, e.g., comprising a heavy chain variable region and a light chain variable region. The term "antigen binding moiety that specifically binds to MUC1" refers to a moiety that is capable of binding to MUC1 or an epitope thereof with sufficient affinity such that a molecule containing the moiety is useful as a diagnostic and / or therapeutic agent targeting MUC1. Antigen binding moieties include antibody fragments as defined herein, e.g., Fab, substituted Fab, or scFv.

[0515] The terms "anti-MUCl antibody" and "MUCl binding antibody" refer to an antibody that is capable of binding to MUCl or an epitope thereof with sufficient affinity.

[0516] The term "antibody-dependent cellular cytotoxicity," "antibody-dependent cell-mediated cytotoxicity," or "ADCC" is a mechanism of inducing cell death that relies on the interaction of antibody-coated target cells with effector cells with lytic activity (such as natural killer cells (NK), monocytes, macrophages, and neutrophils) via Fc gamma receptors (Fc gamma R) expressed on effector cells. For example, NK cells express Fc gamma RIIIa, while monocytes express Fc gamma RI, Fc gamma RII, and Fc gamma RIIIa. The ADCC activity of the antibodies provided herein can be assessed using in vitro assays using antigen-expressing cells as target cells and NK cells as effector cells. Cell lysis is detected based on markers released from the lysed cells (e.g., radioactive substrates, fluorescent dyes, or native intracellular proteins).

[0517] The term "antibody-dependent cellular phagocytosis (ADCP)" refers to a mechanism by which antibody-coated target cells are eliminated by internalization by phagocytes, such as macrophages or dendritic cells.

[0518] The term "complement-dependent cytotoxicity" or "CDC" refers to a mechanism of cell death induction in which the Fc effector domain of a target-bound antibody binds to and activates the complement component C1q, which in turn activates the complement cascade, leading to target cell death. Activation of complement can also result in the deposition of complement components on the surface of target cells, which promote CDC by binding to complement receptors (e.g., CR3) on leukocytes.

[0519] The term "nucleic acid" is used interchangeably with the term "polynucleotide" in this article, and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or connections, which are synthetic, naturally occurring, and non-naturally occurring, with binding properties similar to reference nucleic acids, and metabolized in a manner similar to reference nucleotides. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral-methylphosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs). "Isolated nucleic acid" refers to a nucleic acid molecule separated from the components of its natural environment. The isolated nucleic acid encoding a polypeptide or fusion protein refers to one or more nucleic acid molecules encoding a polypeptide or fusion protein, including one or more nucleic acid molecules in a single vector or a separate vector, and one or more nucleic acid molecules present in one or more positions in a host cell. Unless otherwise indicated, specific nucleic acid sequences also implicitly encompass variants (e.g., degenerate codon substitutions) and complementary sequences of conservative modifications thereof, as well as sequences explicitly indicated. Specifically, as described in detail below, degenerate codon substitutions can be obtained by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.

[0520] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. Unless otherwise indicated, a particular polypeptide sequence also implicitly encompasses conservatively modified variants thereof.

[0521] The term sequence "identity" refers to the degree (percentage) to which the amino acids / nucleic acids of the two sequences are identical at equivalent positions when two sequences are optimally aligned, introducing gaps when necessary, to obtain maximum sequence identity percentage, and not considering any conservative substitutions as part of sequence identity. For measuring sequence identity percentage, alignment can be achieved by techniques known in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine the parameters applicable to measuring alignment, including any algorithm required for achieving maximum alignment over the full length of the compared sequences.

[0522] The term "vector" means a polynucleotide molecule capable of transporting another polynucleotide connected thereto. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop, wherein additional DNA segments can be connected. Another type of vector is a viral vector, such as an adeno-associated viral vector (AAV or AAV2), in which additional DNA segments can be connected to the viral genome. Some vectors can replicate autonomously (for example, bacterial vectors and additional mammalian vectors with bacterial replication origins) in the host cell in which they are introduced. Other vectors (for example, non-additional mammalian vectors) can be integrated into the genome of the host cell after being introduced into the host cell, thereby replicating together with the host genome. The term "expression vector" or "expression construct" refers to a vector that can transform a host cell and contains a nucleic acid sequence for the expression of one or more heterologous coding regions that are operably connected thereto, including guidance and / or control (together with the host cell). Expression constructs can include but are not limited to affecting or controlling transcription, translation and affecting the sequence of RNA splicing of the coding region operably connected thereto when there are introns.

[0523] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including the offspring of such cells. Host cells include "transformants" and "transformed cells," which include primary transformed cells and offspring derived therefrom, without regard to the number of passages. Offspring may not be identical to the parent cell in nucleic acid content, but may contain mutations. Mutant offspring having the same function or biological activity as screened or selected in the initial transformed cells are included herein. Host cells include prokaryotic and eukaryotic host cells, wherein eukaryotic host cells include, but are not limited to, mammalian cells, insect cell lines, plant cells, and fungal cells. Mammalian host cells include humans, mice, rats, dogs, monkeys, pigs, goats, cattle, horses, and hamster cells, including but not limited to Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, and HEK-293 cells.Fungal cells include yeast and filamentous fungal cells, including, for example, Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia truncatula, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia sp., Saccharomyces cerevisiae, Saccharomyces cerevisiae, Hansenula polymorpha, polymorpha), Kluyveromyces spp., Kluyveromyces lactis, Candida albicans, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Trichoderma reesei, Chrysosporium lucknowense, Fusarium sp., Fusarium gramineum, Fusarium venenatum, Physcomitrella patens, and Neurospora crassa. Pichia, any Saccharomyces spp., Hansenula polymorpha, any Kluyveromyces spp., Candida albicans, any Aspergillus spp., Trichoderma reesei, Chrysosporium lucknowense, any Fusarium spp., Yarrowia lipolytica, and Neurospora crassa.

[0524] The term "alkyl" refers to a saturated straight-chain or branched aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., C 1-20 The alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (i.e., C 1-12 alkyl), more preferably an alkyl group having 1 to 6 carbon atoms (i.e., C 1-6 Non-limiting examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 ,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. The alkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0525] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkenyl group is preferably an alkenyl group having 2 to 6 carbon atoms (i.e., C 2-6Alkenyl). Non-limiting examples include: ethenyl, propenyl, isopropenyl, butenyl, etc. Alkenyl can be substituted or unsubstituted. When substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.

[0526] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples include methoxy, ethoxy, propoxy, and butoxy. Alkoxy groups may be substituted or unsubstituted. When substituted, they may be substituted at any available point of attachment, with the substituent preferably being selected from one or more of a D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.

[0527] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic all-carbon ring (i.e., a monocyclic cycloalkyl) or a polycyclic ring system (i.e., a polycyclic cycloalkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 3- to 20-membered cycloalkyl). The cycloalkyl group is preferably a cycloalkyl group having 3 to 12 ring atoms (i.e., a 3- to 12-membered cycloalkyl group), more preferably a cycloalkyl group having 3 to 8 ring atoms (i.e., a 3- to 8-membered cycloalkyl group), and most preferably a cycloalkyl group having 3 to 6 ring atoms (i.e., a 3- to 6-membered cycloalkyl group).

[0528] Non-limiting examples of the monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl and cyclooctyl.

[0529] The polycyclic cycloalkyl group includes: spirocycloalkyl group, fused cycloalkyl group and bridged cycloalkyl group.

[0530] The term "spiroalkyl" refers to a polycyclic ring system having a common carbon atom (called a spiro atom) between the rings, which may contain one or more double bonds within the ring, or one or more heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized to form nitrogen oxides; the sulfur may be optionally oxoed to form sulfoxides or sulfones, but does not include -OO-, -OS- or -SS-), provided that it contains at least one all-carbon ring and the point of attachment is on the all-carbon ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered spiroalkyl). The spiroalkyl preferably has 6 to 14 ring atoms (i.e., a 6- to 14-membered spiroalkyl), and more preferably has 7 to 10 ring atoms (i.e., a 7- to 10-membered spiroalkyl). The spirocycloalkyl group includes a monospirocycloalkyl group and a polyspirocycloalkyl group (such as a bispirocycloalkyl group, etc.), preferably a monospirocycloalkyl group or a bispirocycloalkyl group, more preferably a 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered or 7-membered / 6-membered monospirocycloalkyl group. Non-limiting examples include:

[0531] Its connection point can be at any position;

[0532] wait.

[0533] The term "fused cycloalkyl" refers to a polycyclic ring system in which two adjacent carbon atoms are shared between the rings, which is a monocyclic cycloalkyl fused to one or more monocyclic cycloalkyls, or a monocyclic cycloalkyl fused to one or more heterocyclyls, aryls, or heteroaryls, wherein the point of attachment is on the monocyclic cycloalkyl, which may contain one or more double bonds within the ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused cycloalkyl). The fused cycloalkyl is preferably a fused cycloalkyl having 6 to 14 ring atoms (i.e., a 6- to 14-membered fused cycloalkyl), more preferably a fused cycloalkyl having 7 to 10 ring atoms (i.e., a 7- to 10-membered fused cycloalkyl). The fused cycloalkyl group includes bicyclic fused cycloalkyl groups and polycyclic fused cycloalkyl groups (such as tricyclic fused cycloalkyl groups, tetracyclic fused cycloalkyl groups, etc.), preferably bicyclic fused cycloalkyl groups or tricyclic fused cycloalkyl groups, more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered or 7-membered / 6-membered bicyclic fused cycloalkyl groups. Non-limiting examples include: Its connection point can be at any position; wait.

[0534] The term "bridged cycloalkyl" refers to a full carbon polycyclic ring system that shares two carbon atoms that are not directly connected between the rings, which may contain one or more double bonds within the ring and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., a 5 to 20-membered bridged cycloalkyl). The bridged cycloalkyl preferably has a bridged cycloalkyl of 6 to 14 carbon atoms (i.e., a 6 to 14-membered bridged cycloalkyl), more preferably a bridged cycloalkyl of 7 to 10 carbon atoms (i.e., a 7 to 10-membered bridged cycloalkyl). The bridged cycloalkyl includes bicyclic bridged cycloalkyl and polycyclic bridged cycloalkyl (e.g., tricyclic bridged cycloalkyl, tetracyclic bridged cycloalkyl, etc.), preferably bicyclic bridged cycloalkyl or tricyclic bridged cycloalkyl. Non-limiting examples include:

[0535] Its connection point can be at any position.

[0536] The cycloalkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0537] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic heterocycle (i.e., a monocyclic heterocyclyl) or a polycyclic heterocyclic ring system (i.e., a polycyclic heterocyclyl) containing at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxoed, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-) in the ring, and having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 3- to 20-membered heterocyclyl). The heterocyclic group is preferably a heterocyclic group having 3 to 12 ring atoms (i.e., a 3- to 12-membered heterocyclic group), for example, a 4- to 12-membered heterocyclic group containing at least one nitrogen atom; further preferably, a heterocyclic group having 3 to 8 ring atoms (i.e., a 3- to 8-membered heterocyclic group); more preferably, a heterocyclic group having 3 to 6 ring atoms (i.e., a 3- to 6-membered heterocyclic group); and most preferably, a heterocyclic group having 5 or 6 ring atoms (i.e., a 5- or 6-membered heterocyclic group).

[0538] Non-limiting examples of the monocyclic heterocyclic group include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and homopiperazinyl.

[0539] The polycyclic heterocyclic group includes a spiro heterocyclic group, a fused heterocyclic group and a bridged heterocyclic group.

[0540] The term "spiroheterocyclyl" refers to a polycyclic heterocyclic ring system in which the rings share one atom (called a spiro atom), which may contain one or more double bonds in the ring and at least one (e.g., 1, 2, 3 or 4) heteroatom selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS- or -SS-), provided that it contains at least one monocyclic heterocyclic group and the point of attachment is on the monocyclic heterocyclic group, which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered spiroheterocyclyl). The spiro heterocyclic radical preferably has a spiro heterocyclic radical (i.e., a 6 to 14 yuan spiro heterocyclic radical) of 6 to 14 ring atoms, more preferably a spiro heterocyclic radical (i.e., a 7 to 10 yuan spiro heterocyclic radical) with 7 to 10 ring atoms. The spiro heterocyclic radical includes monospiro heterocyclic radical and polyspiro heterocyclic radical (such as dispiro heterocyclic radical etc.), preferably monospiro heterocyclic radical or dispiro heterocyclic radical, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan monospiro heterocyclic radical. Non-limiting examples include:

[0541] wait.

[0542] The term "fused heterocyclyl" refers to a polycyclic heterocyclic ring system that shares two adjacent atoms between the rings, which may contain one or more double bonds within the ring and at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS-, or -SS-), which is a monocyclic heterocyclyl fused to one or more monocyclic heterocyclyls, or a monocyclic heterocyclyl fused to one or more cycloalkyl, aryl, or heteroaryl groups, wherein the point of attachment is on the monocyclic heterocyclyl, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused heterocyclyl). The fused heterocyclic radical preferably has a fused heterocyclic radical of 6 to 14 ring atoms (i.e., a 6 to 14-membered fused heterocyclic radical), more preferably a fused heterocyclic radical of 7 to 10 ring atoms (i.e., a 7 to 10-membered fused heterocyclic radical). The fused heterocyclic radical includes bicyclic and polycyclic fused heterocyclic radicals (such as tricyclic fused heterocyclic radicals, tetracyclic fused heterocyclic radicals, etc.), preferably bicyclic fused heterocyclic radicals or tricyclic fused heterocyclic radicals, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan bicyclic fused heterocyclic radicals. Non-limiting examples include:

[0543] wait.

[0544] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic ring system that shares two atoms that are not directly connected between the rings, which may contain one or more double bonds within the ring and at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS-, or -SS-), and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered bridged heterocyclic group). The bridged heterocyclic group is preferably a bridged heterocyclic group having 6 to 14 ring atoms (i.e., a 6- to 14-membered bridged heterocyclic group), and more preferably a bridged heterocyclic group having 7 to 10 ring atoms (i.e., a 7- to 10-membered bridged heterocyclic group). According to the number of constituent rings, heterocyclic groups can be divided into bicyclic bridged heterocyclic groups and polycyclic bridged heterocyclic groups (such as tricyclic bridged heterocyclic groups, tetracyclic bridged heterocyclic groups, etc.), preferably bicyclic bridged heterocyclic groups or tricyclic bridged heterocyclic groups. Non-limiting examples include:

[0545] wait.

[0546] The heterocyclic group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment. The substituents are preferably selected from one or more of a D atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclic group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group.

[0547] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aromatic group) or a polycyclic aromatic ring system (i.e., a polycyclic aromatic group) having a conjugated π electron system, which has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., a 6- to 14-membered aromatic group). The aryl group is preferably an aromatic group having 6 to 10 ring atoms (i.e., a 6- to 10-membered aromatic group). The monocyclic aromatic group is, for example, a phenyl group. Non-limiting examples of the polycyclic aromatic group include: naphthyl, anthracenyl, phenanthrenyl, etc. The polycyclic aromatic group also includes a phenyl group fused with one or more heterocyclic groups or cycloalkyl groups, or a naphthyl group fused with one or more heterocyclic groups or cycloalkyl groups, wherein the connection point is on the phenyl group or naphthyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system, non-limiting examples include:

[0548] wait.

[0549] The aryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0550] The term "heteroaryl" refers to a monocyclic heteroaromatic ring (i.e., a monocyclic heteroaryl) or a polycyclic heteroaromatic ring system (i.e., a polycyclic heteroaryl) having a conjugated π electron system, which contains at least one (e.g., 1, 2, 3 or 4) heteroatom selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS- or -SS-), and has 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., a 5- to 14-membered heteroaryl). The heteroaryl group is preferably a heteroaryl group having 5 to 10 ring atoms (i.e., a 5- to 10-membered heteroaryl group), more preferably a monocyclic heteroaryl group having 5 or 6 ring atoms (i.e., a 5- or 6-membered monocyclic heteroaryl group) or a bicyclic heteroaryl group having 8 to 10 ring atoms (i.e., an 8- to 10-membered bicyclic heteroaryl group), and most preferably a 5- or 6-membered monocyclic heteroaryl group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulfur in the ring, or an 8- to 10-membered bicyclic heteroaryl group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulfur in the ring.

[0551] The monocyclic heteroaryl groups include, but are not limited to, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, N-alkylpyridone (e.g. etc.), pyrazinyl, pyridazinyl, etc.

[0552] The polycyclic heteroaryl groups include, but are not limited to, indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophenyl, quinazolinyl, benzothiazolyl, carbazolyl, and the like. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused to one or more aromatic groups, wherein the point of attachment is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused to one or more cycloalkyl or heterocyclic groups, wherein the point of attachment is on the monocyclic heteroaromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. Non-limiting examples include:

[0553]

[0554] wait.

[0555] The heteroaryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0556] The above-mentioned cycloalkyl, heterocyclyl, aryl and heteroaryl groups include residues derived from a parent ring atom by removing one hydrogen atom, or residues derived from the same parent ring atom or two different ring atoms by removing two hydrogen atoms, i.e., "divalent cycloalkyl", "divalent heterocyclyl", "arylene" and "heteroarylene".

[0557] In the chemical structure of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or or include both and Two configurations.

[0558] The compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, for example, 2 H (deuterium, D), 3 H (tritium, T), 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 p、 33 p、 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I, etc., preferably deuterium.

[0559] Compared to non-deuterated drugs, deuterated drugs offer advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, whether radioactive or not, are encompassed by this disclosure. Each available hydrogen atom attached to a carbon atom can be independently replaced with a deuterium atom, where the deuterium replacement can be partial or complete. Partial deuterium replacement refers to the replacement of at least one hydrogen atom with at least one deuterium atom.

[0560] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0561] The term "pharmaceutical composition" refers to a mixture containing one or more anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof or pharmaceutically acceptable salts thereof, as described herein, and other chemical components, such as physiologically / pharmaceutically acceptable carriers and excipients.

[0562] The term "pharmaceutically acceptable carrier" refers to a component of a pharmaceutical formulation that is different from the active ingredient and is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0563] The term "subject" or "individual" includes humans and non-human animals. Non-human animals include all vertebrates (e.g., mammals and non-mammals) such as non-human primates, sheep, dogs, cows, chickens, amphibians and reptiles. Unless otherwise indicated, the terms "patient" or "subject" are used interchangeably herein. In certain embodiments, the individual or subject is a human.

[0564] "Administering" or "administering," as it applies to an animal, human, experimental subject, cell, tissue, organ or biological fluid, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent or composition with the animal, human, subject, cell, tissue, organ or biological fluid.

[0565] The term "sample" refers to a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present in a subject. Exemplary samples are biological fluids such as blood, serum and serosal fluid, plasma, lymph, urine, saliva, cystic fluid, tears, feces, sputum, mucosal secretions of secretory tissues and organs, vaginal secretions, ascites, pleura, pericardium, peritoneum, fluids of the abdominal cavity and other body cavities, fluids collected by bronchial lavage, synovial fluid, liquid solutions in contact with a subject or biological source, such as cell and organ culture media (including cell or organ conditioned media), lavage fluids, etc., tissue biopsy samples, fine needle aspirations, surgically resected tissues, organ cultures, or cell cultures.

[0566] "Treatment" and "treatment" (and grammatical variations thereof) refer to clinical interventions that attempt to alter the natural course of the individual being treated, and can be implemented for prevention or during the course of clinical pathology. The desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, alleviating / reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the disease state, and remission or improved prognosis. In some embodiments, the antibodies or antigen-binding fragments thereof, antigen-binding molecules, or antibody-drug conjugates of the present disclosure are used to delay the development of the disease or slow the progression of the disease.

[0567] "Effective amount" is generally enough to reduce the severity and / or frequency of symptoms, eliminate these symptoms and / or potential causes, prevent symptoms and / or their potential causes from occurring and / or improve or ameliorate the damage (e.g., lung disease) caused by or associated with the disease state. In some embodiments, an effective amount is a therapeutically effective amount or a prophylactic effective amount. A "therapeutically effective amount" is enough to treat a disease state or symptom, particularly a state or symptom associated with the disease state, or otherwise prevent, hinder, delay or reverse the disease state or any other undesirable symptom associated with the disease in any way. A "prophylactic effective amount" is an amount that will have a predetermined preventive effect when administered to a subject, such as preventing or delaying the onset (or recurrence) of the disease state, or reducing the likelihood of the onset (or recurrence) of the disease state or associated symptoms. A complete treatment or prophylactic effect may not occur after administering one dose, but may occur after administering a series of doses. Thus, a therapeutically or prophylactically effective amount can be administered in one or more doses. A "therapeutically effective amount" and a "prophylactically effective amount" can vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic agent or combination of therapeutic agents to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic agent or combination of therapeutic agents include, for example, improved health status of the patient.

[0568] Anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, and antigen-binding molecules that specifically bind to EGFR and MUC1 disclosed herein

[0569] The present disclosure provides anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, and antigen-binding molecules that specifically bind to EGFR and MUC1, which have many advantageous properties, such as good in vitro killing activity, therapeutic activity, safety, pharmacokinetic properties, and drugability (such as yield, purity, and stability).

[0570] Exemplary Anti-MUC1 Antibodies or Antigen-Binding Fragments Thereof

[0571] The embodiments disclosed herein disclose antibody series M4, M6, F4-1, and F4-18. The antibodies or antigen-binding fragments thereof disclosed herein are described below using antibody M4 as an example.

[0572] Exemplary, the anti-MUC1 antibody or antigen-binding fragment thereof disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 4, and LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 5.

[0573] Exemplary, an anti-MUC1 antibody or antigen-binding fragment thereof of the present disclosure comprises a heavy chain variable region and a light chain variable region, wherein HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 17.

[0574] Exemplary, the anti-MUC1 antibody or antigen-binding fragment thereof disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of HCDR1 of the heavy chain variable region is shown in SEQ ID NO: 12, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 13, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 14, and the amino acid sequence of LCDR1 of the light chain variable region is shown in SEQ ID NO: 15, the amino acid sequence of LCDR2 is shown in SEQ ID NO: 16, and the amino acid sequence of LCDR3 is shown in SEQ ID NO: 17.

[0575] Exemplary, the anti-MUC1 antibody or antigen-binding fragment thereof disclosed herein is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody. In some embodiments, it is a chimeric antibody or a fully human antibody. In some embodiments, it is a humanized antibody.

[0576] Exemplarily, the anti-MUC1 antibodies or antigen-binding fragments thereof disclosed herein comprise a framework region (FR) of a human antibody.

[0577] Exemplary, an anti-MUC1 antibody or antigen-binding fragment thereof of the present disclosure, wherein the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 36, 37 or 38, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 39, 40, 41 or 42; or the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 4, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 5.

[0578] Exemplary anti-MUC1 antibodies or antigen-binding fragments thereof disclosed herein, wherein the heavy chain variable region comprises FR1, FR2, FR3 derived from IGHV1-46*01 and FR4 derived from IGHJ6*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 28S, 38K, 40R, 48I, 71A, 73K, 76D, and 82aR; and / or the light chain variable region comprises FR1, FR2, FR3 derived from IGKV1-39*01, 1GKV6-21*02, or IGKV3-11*01 and FR4 derived from IGKJ4*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 3V, 43S, 47W, 49Y, and 60G. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0579] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof comprises an amino acid sequence of SEQ ID NO: 12 in the heavy chain variable region, an amino acid sequence of SEQ ID NO: 13 in the HCDR1, an amino acid sequence of SEQ ID NO: 13 in the HCDR2, and an amino acid sequence of SEQ ID NO: 14 in the HCDR3, and an amino acid sequence of SEQ ID NO: 14 in the FR of the heavy chain variable region, and one or more amino acid substitutions selected from the group consisting of 1E, 28S, 38K, 40R, 48I, 71A, 73K, 76D, and 82aR in the FR of the light chain variable region, and an amino acid sequence of SEQ ID NO: 15 in the LCDR1, an amino acid sequence of SEQ ID NO: 16 in the LCDR2, and an amino acid sequence of SEQ ID NO: 17 in the LCDR3, and one or more amino acid substitutions selected from the group consisting of 3V, 43S, 47W, 49Y, and 60G in the FR of the light chain variable region. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0580] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region HCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 14, and a heavy chain variable region FR comprising one or more amino acid substitutions selected from the group consisting of 1E, 28S, 38K, 40R, 48I, 71A, 73K, 76D, and 82aR; and a light chain variable region LCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and a light chain variable region FR comprising one or more amino acid substitutions selected from the group consisting of 3V, 43S, and 47W. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0581] In some embodiments, the anti-MUC1 antibody or antigen-binding fragment thereof comprises the heavy chain variable region HCDR1 comprising the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprising the amino acid sequence of SEQ ID NO: 14, and the heavy chain variable region FR comprising amino acid substitutions of 1E, 71A, 73K, and 76D; and the light chain variable region LCDR1 comprising the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the light chain variable region FR comprising amino acid substitutions of 43S and 47W. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0582] Exemplary, the anti-MUC1 antibodies or antigen-binding fragments thereof disclosed herein are antibody fragments; in some embodiments, they are selected from Fab, Fab', F(ab')2, Fd, Fv, scFv, dsFv and dAb.

[0583] Exemplary anti-MUC1 antibodies or antigen-binding fragments thereof disclosed herein comprise a heavy chain constant region and a light chain constant region. In some embodiments, the heavy chain constant region is a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region. In some embodiments, the light chain constant region is a human kappa or lambda light chain constant region. In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 69 or 186, and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 70. In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 69, and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 70.

[0584] Exemplary, an anti-MUC1 antibody or antigen-binding fragment thereof of the present disclosure comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 71, 73, 75 or 77, and the light chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 72, 74, 76 or 78.

[0585] Exemplary, the anti-MUC1 antibody or antigen-binding fragment thereof disclosed herein comprises a heavy chain and a light chain, wherein:

[0586] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 71, and the amino acid sequence of the light chain is shown in SEQ ID NO: 72; or

[0587] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 73, and the amino acid sequence of the light chain is shown in SEQ ID NO: 74; or

[0588] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 75, and the amino acid sequence of the light chain is shown in SEQ ID NO: 76; or

[0589] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 77, and the amino acid sequence of the light chain is shown in SEQ ID NO: 78.

[0590] Exemplary, the anti-MUC1 antibody or antigen-binding fragment thereof disclosed herein comprises a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain is shown in SEQ ID NO: 71, and the amino acid sequence of the light chain is shown in SEQ ID NO: 72.

[0591] Exemplarily, the present disclosure also provides an isolated anti-MUC1 antibody or an antigen-binding fragment thereof, which competes with the anti-MUC1 antibody as described in any of the preceding items for binding to human MUC1.

[0592] For example, the anti-MUC1 antibody or antigen-binding fragment thereof isolated by the present disclosure has a concentration of less than 5×10 -8 M (e.g. less than 4×10 -8 M, less than 3×10 -8 M, less than 2.5×10 -8 M, less than 2×10 -8 M, less than 1.5×10 -8 M, less than 1×10 -8 M, less than 9×10 -9 M, less than 8×10 -9 M, less than 7×10 -9 M, less than 6×10 -9 M, less than 5×10 -9 M, less than 4×10 -9 M, less than 3×10 -9 M, less than 2×10 -9 M) binds to human MUC1 with KD values ​​measured by Biacore.

[0593] Exemplary anti-EGFR antibodies or antigen-binding fragments thereof

[0594] The present disclosure provides anti-EGFR antibodies or antigen-binding fragments thereof.

[0595] Exemplary, the anti-EGFR antibody or antigen-binding fragment thereof disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 116, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0596] Exemplary, the anti-EGFR antibody or antigen-binding fragment thereof disclosed herein is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody. In some embodiments, it is a chimeric antibody or a fully human antibody. In some embodiments, it is a humanized antibody.

[0597] Exemplarily, the anti-EGFR antibody or antigen-binding fragment thereof disclosed herein comprises a framework region (FR) of a human antibody.

[0598] Exemplarily, the anti-EGFR antibody or antigen-binding fragment thereof of the present disclosure comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 138, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149.

[0599] Exemplarily, the anti-EGFR antibody or antigen-binding fragment thereof of the present disclosure comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 153, and the light chain comprises the amino acid sequence of SEQ ID NO: 164.

[0600] Exemplary Antigen Binding Molecules That Specifically Bind to EGFR and MUC1

[0601] The presently disclosed embodiments disclose antigen binding molecules that specifically bind to EGFR and MUCl.

[0602] Exemplary, the antigen binding molecules disclosed herein that specifically bind to EGFR and MUC1 comprise at least one antigen binding moiety that specifically binds to EGFR and at least one antigen binding moiety that specifically binds to MUC1, wherein the antigen binding moiety that specifically binds to EGFR comprises a heavy chain variable region EGFR-VH and a light chain variable region EGFR-VL, and the antigen binding moiety that specifically binds to MUC1 comprises a heavy chain variable region MUC1-VH and a light chain variable region MUC1-VL; wherein:

[0603] The HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121.

[0604] Exemplarily, the antigen-binding molecule disclosed herein that specifically binds to EGFR and MUC1 comprises a first chain having a structure represented by formula (a), a second chain having a structure represented by formula (b), a third chain having a structure represented by formula (c), and a fourth chain having a structure represented by formula (d).

[0605] (a) [MUC1-VH]-[CH1]-[Fc1],

[0606] (b) [MUC1-VL]-[CL],

[0607] (c)[EGFR-VH]-[GGGGS]-[Titin]-[Fc2],

[0608] (d)[EGFR-VL]-[GGGGS]-[Obscurin],

[0609] Wherein: the structures shown in formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus.

[0610] Exemplarily, the antigen-binding molecule specifically binding to EGFR and MUC1 disclosed herein has an asymmetric structure molecule comprising four chains, as shown in FIG5 ; wherein the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: The amino acid sequence of NO:121.

[0611] Exemplarily, the antigen-binding molecule that specifically binds to EGFR and MUC1 disclosed herein has an asymmetric structural molecule format comprising four chains, as shown in FIG5 ; wherein the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149.

[0612] Exemplarily, the antigen-binding molecule of the present disclosure that specifically binds to EGFR and MUC1 has: a first chain as shown in SEQ ID NO: 171, a second chain as shown in SEQ ID NO: 74, a third chain as shown in SEQ ID NO: 174, and a fourth chain as shown in SEQ ID NO: 173.

[0613] Exemplarily, the antigen-binding molecule of the present disclosure that specifically binds to EGFR and MUC1 has: a first chain as shown in SEQ ID NO: 178, a second chain as shown in SEQ ID NO: 74, a third chain as shown in SEQ ID NO: 179, and a fourth chain as shown in SEQ ID NO: 173.

[0614] Exemplary antibody-drug conjugates or pharmaceutically acceptable salts thereof

[0615] The embodiments disclosed herein disclose an antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof:

[0616] in:

[0617] Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-;

[0618] R a and R b are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, halogens and C 1-6 alkyl;

[0619] R 1 is a 3- to 6-membered cycloalkyl-C 1-6 Alkyl or 3- to 6-membered cycloalkyl;

[0620] R 2 Selected from hydrogen atoms, C 1-6 Haloalkyl and 3- to 6-membered cycloalkyl;

[0621] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group;

[0622] m is 0, 1, 2, 3 or 4;

[0623] n is 2 to 8; preferably, n is 4 to 8; more preferably, n is 4 to 6;

[0624] L is the joint unit;

[0625] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1, comprising an antigen-binding moiety that specifically binds to EGFR and an antigen-binding moiety that specifically binds to MUC1, wherein the antigen-binding moiety that specifically binds to EGFR comprises a heavy chain variable region EGFR-VH and a light chain variable region EGFR-VL, and the antigen-binding moiety that specifically binds to MUC1 comprises a heavy chain variable region MUC1-VH and a light chain variable region MUC1-VL; wherein:

[0626] the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121;

[0627] Preferably, the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149;

[0628] More preferably, the antigen-binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 174, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173; or a first chain comprising the amino acid sequence of SEQ ID NO: 178, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 179, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173.

[0629] For example, the antibody-drug conjugate of the general formula (Pc-LYD) disclosed herein or a pharmaceutically acceptable salt thereof is a general formula (Pc-L a -YD) an antibody-drug conjugate or a pharmaceutically acceptable salt thereof:

[0630] in:

[0631] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1 as described above;

[0632] m is 0, 1, 2, 3 or 4;

[0633] n is 2 to 8; preferably, n is 4 to 8; more preferably, n is 4 to 6;

[0634] R 1 is a 3- to 6-membered cycloalkyl-C 1-6 Alkyl or 3- to 6-membered cycloalkyl;

[0635] R 2 Selected from hydrogen atoms, C 1-6 Haloalkyl and 3- to 6-membered cycloalkyl;

[0636] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group;

[0637] W is selected from C 1-6 Alkylene and C 1-6 Alkylene-3 to 6-membered cycloalkyl;

[0638] L 2 is a chemical bond;

[0639] L 3 The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and is optionally selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Deuterated alkyl, C 1-6 substituted by one or more substituents selected from alkoxy and 3- to 6-membered cycloalkyl;

[0640] R 5 A hydrogen atom or C 1-6 alkyl;

[0641] R 6 and R 7 The same or different, and each independently a hydrogen atom or a C 1-6 alkyl.

[0642] Exemplarily, the antibody-drug conjugate of the general formula (Pc-LYD) disclosed herein or a pharmaceutically acceptable salt thereof is an antibody-drug conjugate of the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:

[0643] in:

[0644] n is 2 to 8; preferably, n is 4 to 8; more preferably, n is 4 to 6;

[0645] Pc is an antigen-binding molecule that specifically binds to EGFR and MUC1 as described above.

[0646] Antibody structure

[0647] In certain embodiments, the antibodies provided herein are full-length antibodies.

[0648] In certain embodiments, the antibodies provided herein are antibody fragments.

[0649] In one embodiment, the antibody fragment is a Fab, Fab', Fab'-SH or F(ab')2 fragment, in particular a Fab fragment. "Fab" is a monovalent fragment consisting of the VL, VH, CL and CH1 domains. "Fab fragment" can be produced by papain cleavage of an antibody. "Fab'" contains VL, CL as well as VH and CH1, and also contains a region between the CH1 and CH2 domains so that an interchain disulfide bond can be formed between the two heavy chains of the two Fab' fragments to form a F(ab')2 molecule. "Fab'-SH" is a Fab' fragment in which the cysteine ​​residues in the constant region have a free sulfhydryl group. "F(ab')2" is a bivalent fragment comprising two Fab fragments linked by a disulfide bond at the hinge region.

[0650] In another embodiment, the antibody fragment is a diabody, triabody, or tetrabody. A diabody is an antibody fragment with two antigen-binding sites, which contains a linked VH and VL in the same polypeptide chain (VH-VL). By using a linker that is too short to prevent pairing between the two domains on the same chain, these domains are forced to pair with complementary domains from another chain, thereby generating two antigen-binding sites. The two antigens can be the same or different.

[0651] In another embodiment, the antibody fragment is a single-chain Fab fragment. "Single-chain Fab fragment" or "scFab" is a polypeptide consisting of VH, CH1, VL, CL and a linker, wherein the antibody domain and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL. In one embodiment, the linker is a polypeptide having at least 30 amino acids. In another embodiment, the linker is a polypeptide having between 32 and 50 amino acids. The single-chain Fab fragment is stabilized via the natural disulfide bond between CL and CH1. In addition, these single-chain Fab molecules can be further stabilized by inserting cysteine ​​residues (e.g., position 44 in the heavy chain variable region and position 100 in the light chain variable region, according to Kabat numbering) to produce interchain disulfide bonds.

[0652] In another embodiment, the antibody fragment is an Fv fragment consisting of the VH and VL domains of a single arm of an antibody.

[0653] In another embodiment, the antibody fragment is a single-chain variable fragment (scFv). "scFv" is a fusion protein comprising at least one antibody fragment containing a light chain variable region and at least one antibody fragment containing a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region are continuously connected by a short flexible peptide linker, capable of being expressed as a single-chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise specified, scFv herein can have the VL and VH variable regions in any order, for example, relative to the N-terminus and C-terminus of the polypeptide, the scFv can comprise VL-linker-VH or can comprise VH-linker-VL.

[0654] In another embodiment, the antibody fragment is a dsFv obtained by linking polypeptides in which one amino acid residue in each of VH and VL is substituted with a cysteine ​​residue via a disulfide bond between the cysteine ​​residues. The amino acid residue to be substituted with the cysteine ​​residue can be selected based on the three-dimensional structure prediction of the antibody according to a known method (Protein Engineering. 7: 697 (1994)).

[0655] In another embodiment, the antibody fragment is a single domain antibody (dAb).A single domain antibody is an antibody fragment that comprises all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody.

[0656] In certain embodiments, the antibodies provided herein are chimeric antibodies. In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In another example, a chimeric antibody is a "class-switched" antibody in which the class or subclass has been changed from that of the parent antibody.

[0657] In certain embodiments, antibody is a humanized antibody. Generally, non-human antibodies are passed through humanization to reduce immunogenicity to people, while retaining the specificity and affinity of the parent non-human antibody. Generally, humanized antibodies comprise one or more variable regions, wherein CDR or its portion are derived from non-human antibodies, and FR or its portion are derived from human antibodies. Optionally, humanized antibodies also may comprise a part for human constant region. In some embodiments, some FR residues in humanized antibodies may be substituted with corresponding residues from non-human antibodies (for example, antibodies providing CDR sequences).

[0658] Humanized antibodies and methods for their generation are reviewed in, for example, Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described in, for example, Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Patent Nos. 5,821,337, 7,527,791, 6,982,321 and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing "resurfuacing"); Dall'Acqua et al., Methods 36:43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer 83:252-260 (2000) (describing the "guided selection" method of FR shuffling).

[0659] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al., J. Immunol. 151: 2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light chain variable regions or heavy chain variable regions (see, e.g., Carter et al., Proc. Natl. Acad. Sci. USA, 89: 4285 (1992); and Presta et al., J. Immunol., 151: 2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)); and framework regions obtained by screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272: 10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271: 22611-22618 (1996)).

[0660] Variants of anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof

[0661] In certain embodiments, amino acid sequence variants of the anti-MUC1 antibodies, or antigen-binding fragments thereof, or anti-EGFR antibodies, or antigen-binding fragments thereof, provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibodies. Amino acid sequence variants of the antibodies may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibodies, or by peptide synthesis. Such modifications include, for example, deletions, and / or insertions, and / or substitutions of residues within the amino acid sequence of the anti-MUC1 antibodies, or antigen-binding fragments thereof, or anti-EGFR antibodies, or antigen-binding fragments thereof. Any combination of deletions, insertions, and substitutions may be performed to obtain the final construct, as long as the final construct possesses the desired characteristics, such as antigen binding properties.

[0662] Substitution, insertion, and deletion variants

[0663] In certain embodiments, antibody variants with one or more amino acid substitutions are provided. The sites of interest for substitution mutagenesis include CDRs and FRs. Conservative substitutions are shown under the heading "preferred substitutions" in Table 2. More substantial variations are provided under the heading "exemplary substitutions" in Table 2, and are further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into the antibody of interest, and the product is screened for desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.

[0664] Table 2. Amino acid substitutions

[0665] Based on common side chain properties, amino acids can be grouped as follows:

[0666] (1) Hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;

[0667] (2) Neutral, hydrophilic: Cys, Ser, Thr, Asn, Gln;

[0668] (3) Acidic: Asp, Glu;

[0669] (4) Basic: His, Lys, Arg;

[0670] (5) Residues that affect chain orientation: Gly, Pro;

[0671] (6) Aromatic: Trp, Tyr, Phe.

[0672] Non-conservative substitutions will entail exchanging a member of one of these classes for a member of another class.

[0673] A class of substitution variants involves replacing one or more CDR residues of a parent antibody (e.g., humanized or human antibody). Generally, the variants selected for further study will have changes (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody, and / or will substantially retain certain biological properties of the parent antibody. An exemplary substitution variant is an affinity-matured antibody, which can be readily produced using, for example, affinity maturation techniques based on phage display (e.g., those described herein). In short, one or more CDR residues are mutated, and the variant antibody is displayed on phage, and screened for specific biological activity (e.g., binding affinity). Changes (e.g., substitutions) can be made to CDR, for example, to improve antibody affinity. Such changes can be made to CDR "hot spots," i.e., residues encoded by codons that undergo mutations at high frequency during the somatic maturation process, and / or residues contacting antigens, while binding affinity is tested for the variant VH or VL obtained. In some embodiments of affinity maturation, diversity is introduced into the variable gene selected for maturation by any of a variety of methods (e.g., fallibility PCR, chain shuffling, or oligonucleotide-guided mutagenesis). Then, a secondary library is created. The library is then screened to identify any antibody variant with desired affinity. Another method of introducing diversity relates to a CDR-directed method, in which several CDR residues (e.g., 4-6 residues at a time) are randomized. CDR residues that specifically identify antigen binding can be, for example, identified using alanine scanning mutagenesis or modeling. In particular, HCDR3 and LCDR3 are often targeted.

[0674] In certain embodiments, substitution, insertion or deletion can occur in one or more CDRs, as long as such changes do not substantially reduce the ability of the antibody to bind to antigen. For example, conservative changes (e.g., conservative substitutions, as provided herein) can be made to the CDRs, which do not substantially reduce binding affinity. Such changes can be, for example, outside the antigen contact residues in the CDRs. In certain embodiments of the variant VH and VL sequences provided above, each CDR is unchanged, or contains no more than 1, 2 or 3 amino acid substitutions.

[0675] A method that can be used to identify residues or regions that can be used as mutagenesis targets in antibodies is called "alanine scanning mutagenesis". In this method, a residue or target residue group (e.g., charged residues, such as Arg, Asp, His, Lys, and Glu) is identified and replaced with neutral or negatively charged amino acids (e.g., Ala or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitution. In addition, the contact points between the antibody and the antigen can be identified by studying the crystal structure of the antigen-antibody complex. These contact residues and adjacent residues can be targeted or eliminated as substitution candidates. Variants can be screened to determine whether they contain desired properties.

[0676] Amino acid sequence insertions include amino and / or carboxyl terminal fusions ranging in length from 1 residue to polypeptides containing 100 or more residues, and intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertion variants of antibody molecules include fusions of the N- or C-terminus of an antibody with an enzyme or a polypeptide that extends the serum half-life of the antibody.

[0677] Recombination methods

[0678] Anti-MUCl antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof can be produced using recombinant methods.For these methods, one or more isolated nucleic acids encoding anti-MUCl antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof are provided.

[0679] In one embodiment, the present disclosure provides an isolated nucleic acid encoding an anti-MUC1 antibody or antigen-binding fragment thereof, an anti-EGFR antibody or antigen-binding fragment thereof as described above. Such nucleic acids can be independently encoded by any of the aforementioned polypeptide chains. In another aspect, the present disclosure provides one or more vectors (e.g., expression vectors) comprising such nucleic acids. In another aspect, the present disclosure provides a host cell comprising such nucleic acids. In one embodiment, a method for preparing a polypeptide or fusion protein is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the polypeptide or fusion protein, as provided above, under conditions suitable for expression, and optionally recovering the anti-MUC1 antibody or antigen-binding fragment thereof from the host cell (or host cell culture medium).

[0680] To recombinantly produce an anti-MUC1 antibody or antigen-binding fragment thereof, an anti-EGFR antibody or antigen-binding fragment thereof, nucleic acids encoding the proteins are isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. Such nucleic acids can be readily isolated and sequenced using conventional procedures, or produced by recombinant methods or obtained by chemical synthesis.

[0681] Suitable host cells for cloning or expressing vectors encoding anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof include the prokaryotic or eukaryotic cells described herein. For example, they can be produced in bacteria, particularly when glycosylation and Fc effector functions are not desired. Following expression, the soluble fraction can be isolated from the bacterial cell paste and further purified.

[0682] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for vectors encoding fusion proteins, including fungal and yeast strains. Suitable host cells suitable for expressing fusion proteins can also be derived from multicellular organisms (invertebrates and vertebrates); examples of invertebrate cells include plant and insect cells. Many baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells; plant cell cultures can also be used as hosts, for example, US5959177, US6040498, US6420548, US7125978 and US6417429; vertebrate cells can also be used as hosts, such as mammalian cell lines adapted to growth in suspension. Other examples of suitable mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells; MRC 5 cells; and FS4 cells. Other suitable mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells; and myeloma cell lines such as Y0, NS0, and Sp2 / 0. For review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268.

[0683] Determination

[0684] The anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof, or pharmaceutically acceptable salts thereof, provided herein can be identified, screened, or characterized for their physical / chemical characteristics and / or biological activity by various assays known in the art. In one aspect, the activity of the anti-MUC1 antibodies or antigen-binding fragments thereof, and anti-EGFR antibodies or antigen-binding fragments thereof disclosed herein can be tested, for example, by known methods such as ELISA, Western blotting, etc.

[0685] Treatment methods and administration routes

[0686] Any of the anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates or pharmaceutically acceptable salts thereof provided herein can be used in therapeutic methods. In another aspect, the present disclosure provides the use of anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates or pharmaceutically acceptable salts thereof in the manufacture or preparation of a medicament. In some embodiments, the disease is a disease or condition associated with MUC1 or EGFR. In some embodiments, the disease is a tumor. In some embodiments, the disease is selected from astrocytoma (e.g., anaplastic astrocytoma), glioblastoma, bladder cancer, bone cancer, brain cancer, breast cancer (e.g., breast cancer characterized by BRCA1 and / or BRCA2 mutations), cervical cancer, colorectal cancer (e.g., colon cancer and rectal cancer), fallopian tube cancer, gallbladder cancer, gastric cancer, head and neck cancer, idiopathic myelofibrosis, kidney cancer (e.g., renal cell carcinoma, renal rhabdoid tumor, and Wilms' tumor), leukemia, liver cancer (e.g., hepatocellular carcinoma), esophageal cancer (also known as "esophageal cancer," such as esophageal squamous cell carcinoma), lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, multiple myeloma, neuroblastoma In some embodiments, the cancer is selected from the group consisting of lung cancer, head and neck cancer, esophageal cancer, breast cancer, pancreatic cancer, prostate cancer, thyroid cancer, prostate cancer, thyroid cancer, gastric cancer, ovarian cancer, colorectal cancer, liver cancer, gallbladder cancer, kidney cancer, cervical cancer, and bladder cancer. In some embodiments, the cancer is lung cancer; preferably, non-small cell lung cancer.

[0687] In yet another aspect, a pharmaceutical composition comprising the anti-MUC1 antibody or antigen-binding fragment thereof, anti-EGFR antibody or antigen-binding fragment thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof, or pharmaceutically acceptable salts thereof, is provided, for example, for use in any of the above pharmaceutical uses or therapeutic methods. In one embodiment, the pharmaceutical composition comprises any of the anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof, or pharmaceutically acceptable salts thereof, provided herein, and a pharmaceutically acceptable carrier.

[0688] The anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof, or pharmaceutically acceptable salts thereof, disclosed herein can be used alone or in combination with other agents for treatment. For example, the antibodies disclosed herein can be co-administered with at least one additional therapeutic agent.

[0689] The anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof or pharmaceutically acceptable salts thereof (and any additional therapeutic agents) disclosed herein can be administered by any suitable means, including parenteral, intrapulmonary and intranasal, and if local treatment is required, intralesional administration. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. Administration can be by any appropriate route, for example, by injection, such as intravenous or subcutaneous injection, which depends in part on whether the administration is short-term or long-term. A variety of dosing schedules are contemplated herein, including, but not limited to, single or multiple administrations at multiple time points, bolus administration and pulse infusion.

[0690] The anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof, or pharmaceutically acceptable salts thereof, disclosed herein will be formulated, dosed, and administered in a manner consistent with good medical practice. Factors to be considered in this context include the specific condition being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the condition, the site of delivery of the agent, the method of administration, the timing of administration, and other factors known to medical practitioners. The anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof, or pharmaceutically acceptable salts thereof, may be formulated with or without one or more agents currently used to prevent or treat the condition. The effective amount of such other agents depends on the amount present in the pharmaceutical composition, the type of condition or treatment, and other factors. These are generally used in the same dosages and routes of administration as described herein, or at about 1 to 99% of the dosages described herein, or at other dosages and by any route determined empirically / clinically appropriate.

[0691] For the prevention or treatment of disease, the appropriate dosage of the anti-MUC1 antibodies or antigen-binding fragments thereof, anti-EGFR antibodies or antigen-binding fragments thereof, antigen-binding molecules that specifically bind to EGFR and MUC1, and antibody-drug conjugates thereof, or pharmaceutically acceptable salts thereof (when used alone or in combination with one or more other additional therapeutic agents) disclosed herein will depend on the type of disease to be treated, the type of therapeutic molecule, the severity and course of the disease, whether it is administered for preventive or therapeutic purposes, previous treatments, the patient's clinical history and response to the therapeutic molecule, and the judgment of the attending physician. The therapeutic molecule is appropriately administered to the patient at one time or over a series of treatments.

[0692] Products

[0693] In another aspect of the present disclosure, an article (e.g., a kit) is provided that contains materials that can be used to treat, prevent, and / or diagnose the above-mentioned conditions. The article comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, and the like. The container can be formed from various materials such as glass or plastic. The container contains a composition that is effective for treating, preventing, and / or diagnosing the condition, either alone or in combination with another composition, and may have a sterile access port (e.g., the container may be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an anti-MUC1 antibody or antigen-binding fragment thereof, an anti-EGFR antibody or antigen-binding fragment thereof, an antigen-binding molecule that specifically binds to EGFR and MUC1, and an antibody-drug conjugate thereof, or a pharmaceutically acceptable salt thereof, of the present disclosure. The label or package insert indicates that the composition is to be used to treat the selected condition. In addition, the article may comprise: (a) a first container in which a composition is housed, wherein the composition comprises an active molecule of the present disclosure; and (b) a second container in which a composition is housed, wherein the composition comprises an additional cytotoxic agent or a therapeutic agent of other aspects. The article in this embodiment of the present disclosure may further comprise a package insert indicating that the composition can be used to treat a specific condition. Alternatively, or additionally, the article may further comprise a second (or third) container, wherein the second (or third) container comprises a pharmaceutically acceptable buffer. From a commercial and user standpoint, it may further comprise other materials required, including other buffers, diluents, filters, needles and syringes.

[0694] The present disclosure is further described below with reference to the following examples and test cases, but these examples and test cases are not intended to limit the scope of the present disclosure. Experimental methods not specifying specific conditions in the examples or test cases of this disclosure generally follow conventional conditions, such as those in the Cold Spring Harbor Laboratory Manual of Antibody Techniques and the Molecular Cloning Manual, or the conditions recommended by the raw material or product manufacturer. Reagents and materials not specifying their sources were purchased commercially.

[0695] Example

[0696] Example 1: Preparation of MUC1 antigen

[0697] Using the UniProt MUC1 antigen (human MUC1 protein, UniProt No.: P15941) as a MUC1 template, the amino acid sequences of the antigens and detection proteins used in this disclosure were designed. Optionally, various tags, such as a His tag or Fc tag, were fused to the MUC1 protein. These proteins were cloned into the pTT5 vector (Biovector, CAT#102762), transiently expressed in 293 cells, and purified to obtain the antigens and detection proteins disclosed herein.

[0698] The His-tagged extracellular domain of the MUC1-C protein (abbreviated as MUC1-CL-6xHis) sequence serves as an immune antigen and detection reagent;

[0699] Note: The underlined part is the 6×His tag, and the bold part is the extracellular domain of MUC1 protein.

[0700] The extracellular domain of the MUC1-C protein and the Human-IgG1-Fc fusion protein sequence (abbreviated as: hMUC1-CL-Fc) were used as immunogens;

[0701] Note: The underlined part is the Human-IgG1-Fc part, and the bold part is the extracellular domain of MUC1 protein.

[0702] At the same time, the Cyno-MUC1-C protein extracellular domain and Human-IgG1-Fc fusion protein sequence (abbreviated as: Cyno MUC1-C-Fc) was used as a detection reagent;

[0703] Note: The underlined part is the Human-IgG1-Fc part, and the bold part is the extracellular domain of Cyno-MUC1 protein.

[0704] Example 2: Purification of MUC1-related recombinant proteins

[0705] 1. Purification steps of recombinant proteins with His tags

[0706] The cell expression supernatant sample was centrifuged at high speed to remove impurities. The nickel column was balanced with a PBS solution containing 20mM imidazole and rinsed 2-5 times the column volume. The replaced cell supernatant sample was placed on a Ni Sepharose excel column (GE, 17-3712-02). The column was rinsed with PBS solution until the A280 reading dropped to the baseline. The chromatography column was then rinsed with PBS+20mM imidazole to remove non-specifically bound miscellaneous proteins and the effluent was collected. The target protein was then eluted with a PBS solution containing 300mM imidazole, and the elution peak was collected. The target protein was exchanged with PBS using a concentrator tube and concentrated to an appropriate concentration. The resulting protein was identified as correct by electrophoresis, peptide mapping, and LC-MS and then allocated for use. MUC1-CL-6xHis with a His tag was obtained and used as a detection reagent for the antibody disclosed herein.

[0707] 2. Purification steps of MUC1-CL-Fc fusion protein

[0708] The cell expression supernatant sample was centrifuged at high speed to remove impurities, and the supernatant was subjected to MabSelect Sure (GE, 17-5438-01) affinity chromatography. The MabSelect Sure chromatography column was first regenerated with 0.2M NaOH, and then the column was balanced with PBS. After the supernatant was combined, it was washed with PBS until the A280 reading dropped to the baseline. The target protein was eluted with 0.1M acetate buffer at pH 3.5 and neutralized with 1M Tris-HCl. The target protein was exchanged into PBS using a concentrator tube and concentrated to an appropriate concentration. The resulting protein was subjected to electrophoresis and LC-MS identification and then aliquoted for use. This method was used to purify the MUC1-CL-Fc fusion protein, and this method can also be used to purify the antibody protein disclosed herein.

[0709] 3. Purification steps for hybridoma screening of antibody samples:

[0710] The cell expression supernatant was centrifuged at high speed to remove impurities. The supernatant was then added to Protein A magnetic beads (SM003100) and incubated at room temperature with shaking for 3 hours. The beads were washed three times with PBS and once with ultrapure water. The target protein was eluted with 0.1M acetate buffer at pH 3.0 and neutralized with 1M Tris-HCl. The target protein was transferred to PBS using a concentrator tube and concentrated to an appropriate concentration. The resulting protein was confirmed by electrophoresis and LC-MS, and then aliquoted for use.

[0711] Example 3: Mouse Immunization Scheme for Murine Anti-MUCl-C Antibody and Hybridoma Antibody Production

[0712] 1. Mouse immunization

[0713] Anti-human MUC1-C antibodies were generated by immunizing mice. Female Balb / c and SJL white mice, 6-8 weeks old (Shanghai Slake Laboratory Animal Co., Ltd., Animal Production License No. SCXK(Shanghai)2017-0005) were used. Mice were housed in an SPF-grade laboratory environment for one week under a 12 / 12 hr light / dark cycle, a temperature of 20-25°C, and a humidity of 40-60%. Acclimated mice were immunized according to the following protocol.

[0714] Immunization plan 1: Immunization with protein antigen (hMUC1 CL-Fc). Gold Adjuvant (Sigma) and Thermo Alum (Thermo) adjuvant cross immunization. Protein antigen (hMUC1 CL-Fc) and adjuvant ( Gold Adjuvant) in a 1:1 ratio and inoculated after emulsification. Protein antigen (hMUC1 CL-Fc) and adjuvant (Thermo Alum) ratio is 3:1, and the mixture is shaken and then inoculated. 50μg / mouse / time (primary immunization), 25μg / mouse / time (routine immunization), 50μg / mouse / time (boost immunization). The immunization time is 0, 14, 34, 48, and 78 days. Blood is collected on days 26, 40, 57, and 82 to determine the antibody titer in the mouse serum. After the 4th-5th immunization, the antibody titer in the mouse serum is determined by ELISA, and mice with high antibody titers in the serum and titers tending to a plateau are selected for spleen cell fusion. 3 days before spleen cell fusion, boost immunization is performed by intraperitoneal (ip) injection of 50μg / mouse of protein antigen (hMUC1 CL-Fc) and an antigen solution prepared with normal saline or intraperitoneal (ip) injection of 1×10 7 Cell antigen solution after cells / cells are resuspended in phosphate buffer solution.

[0715] Immunization scheme 2: Cross-immunization using protein antigen (hMUC1-CL-His) and cell antigen (CHO-K1-MUC1-C). Gold Adjuvant (Sigma) and Thermo Alum (Thermo) adjuvant cross immunization. Protein antigen (hMUC1-CL-His) and adjuvant ( The ratio of hMUC1-CL-Fc to adjuvant (Thermo Alum) ratio of 3:1, shake and mix before vaccination. 50 μg / mouse / time (primary immunization), 25 μg / mouse / time (routine immunization), 50 μg / mouse / time (boost immunization); 1×10 7 Cells / mouse / time. Cell antigens were resuspended in phosphate buffer solution and then inoculated. The inoculation time was 0, 14, 34, 48, 69, and 86 days. Blood was collected on days 26, 40, 57, 82, and 96. After the 5th to 9th immunization, the antibody titer in the mouse serum was determined by ELISA. Mice with high antibody titers in the serum and titers approaching a plateau were selected, and their spleens were removed for spleen cell fusion. Three days before spleen cell fusion, boost immunization was performed by intraperitoneal (ip) injection of 1×10 7 Cell antigen solution after cells / cell are resuspended in phosphate buffer solution.

[0716] Immunization scheme 3: Cross-immunization using protein antigen (hMUC1-CL-Fc) and cell antigen (CHO-K1-MUC1-C). Gold Adjuvant (Sigma) and Thermo Alum (Thermo) adjuvant cross immunization. Protein antigen (hMUC1-CL-Fc) and adjuvant ( The ratio of hMUC1-CL-Fc antigen and adjuvant (Thermo Alum) ratio of 3:1, shake and mix before vaccination. 50 μg / mouse / time (primary immunization), 25 μg / mouse / time (routine immunization), 50 μg / mouse / time (boost immunization); 1×10 7 Cells / mouse / dose. Cell antigens were resuspended in phosphate buffered saline prior to inoculation. Vaccinations were performed on days 0, 12, 25, 40, 55, 112, 127, and 156. Blood samples were collected on days 21, 35, 49, 63, 108, and 154. After the fifth to eighth immunization, antibody titers in mouse serum were determined by ELISA. Mice with high serum antibody titers that plateaued were selected and their spleens harvested for splenocyte fusion. Three days prior to splenocyte fusion, booster immunizations were performed with an intraperitoneal (ip) injection of 50 μg / mouse of a protein antigen (hMUC1-CL-Fc) solution in saline.

[0717] Immunization scheme 4: Cross-immunization using protein antigen (hMUC1-CL-Fc) and cell antigen (HEK293-MUC1-C). Gold Adjuvant (Sigma) and Thermo Alum (Thermo) adjuvant cross immunization. Protein antigen (hMUC1-CL-Fc) and adjuvant ( The ratio of hMUC1-CL-Fc to adjuvant (Thermo Alum) ratio of 3:1, shake and mix before vaccination. 50μg / mouse / time (primary immunization), 25μg / mouse / time (routine immunization), 50μg / mouse / time (boost immunization). Cell antigen (HEK293-MUC1-C) immunization uses 1×10 7 Cells / mouse / dose; cell antigens were resuspended in phosphate buffered saline prior to inoculation. Vaccinations were performed on days 0, 14, 28, and 42. Blood samples were collected on days 10 and 38. After the third and fourth immunizations, antibody titers in mouse serum were determined by ELISA. Mice with high serum antibody titers that plateaued were selected for spleen cell fusion. Three days prior to spleen cell fusion, a booster immunization was performed with an intraperitoneal (ip) injection of 50 μg / mouse of a protein antigen (hMUC1-CL-Fc) solution in saline.

[0718] 2. Spleen cell fusion

[0719] The optimized electrofusion method was used to combine spleen lymphocytes with myeloma cells Sp2 / 0 cells ( CRL-8287 TM ) were fused to obtain hybridoma cells.

[0720] Based on spleen cell count results, resuspend the fused hybridoma cells at a density of 3-4 × 10^5 / mL in complete culture medium (IMDM medium containing 20% ​​FBS, 1× HAT, and 1× OPI) and seed 150 μL / well in a 96-well plate. After incubation at 37°C, 5% CO2 for 4-5 days, remove the supernatant and add 200 μL / well of HT complete culture medium (IMDM medium containing 20% ​​FBS, 1× HAT, and 1× OPI). Incubate at 37°C, 5% CO2 for 2 days before ELISA analysis.

[0721] Example 4: Screening of mouse anti-MUCl-C hybridoma antibodies

[0722] 1. ELISA experiment of hybridoma supernatant antibody binding to hMUC1-CL-his protein

[0723] Human hMUC1-CL-his protein was diluted to a concentration of 1 μg / mL in PBS buffer (pH 7.4) and added to a 96-well microtiter plate (Corning, Cat. No. CLS3590-100EA) at a volume of 100 μL / well. The plate was incubated at 4°C for 16-18 hours. After discarding the liquid, 200 μL / well of blocking solution (5% skim milk powder (Sangon Biotechnology, Cat. No. A600669-0250) diluted in PBS was added and the plate was incubated at 37°C for 1.5 hours. After blocking, the blocking solution was discarded and the plate was washed three times with PBST buffer (pH 7.4 PBS containing 0.1% Tween-20). Then, 100 μL / well of hybridoma supernatant was added and the plate was incubated at 37°C for 1 hour. After incubation, the plate was washed five times with PBST and 50 μL / well of secondary antibody (Jackson ImmunoResearch, Cat. No. 1115-035-003) diluted in 2% MPBS was added. The plate was incubated at 37°C for 1 hour. After washing the plate five times with PBST, 50 μL / well of TMB chromogenic substrate (KPL, Cat. No. 52-00-03) was added and incubated at room temperature for 5-10 minutes. The reaction was terminated by adding 50 μL / well of 1 M H2SO4. The absorbance was read at 450 nm using a VERSAmax microplate reader (Molecular Devices). The results are shown in the following table.

[0724] Table 3. ELISA results of hybridoma supernatant binding to human MUC1-CL-his antigen

[0725] 2. Mirrorball experiment of hybridoma supernatant antibodies binding to human MUC1-C cell line

[0726] HCC827-human-MUC1-C (in-house constructed overexpression stable cell line), CHOK1-cyno-MUC1-C (in-house constructed overexpression stable cell line) or CHOK1-WT cells were digested and washed once with PBS buffer. After that, they were centrifuged at 1000 rpm for 5 min and treated with CellTracker diluted in PBS buffer at a final concentration of 50 nM. TMResuspend the cells (cell density: 1E6 / mL) in Green CMFDA dye (Thermo Fisher Scientific (China) Co., Ltd., Catalog No. C7025) and incubate in an incubator for 30 minutes. After incubation, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, wash once with PBS containing 1% FBS (Gibco, Catalog No. 10100147), and centrifuge again. Resuspend the cells in PBS buffer (final density: 1-2E5 / mL). APC-conjugated fluorescent secondary antibody (BD biosciences, Catalog No. 550826) was added at a dilution of 1:200. The cell mixture was plated into a 384-well plate (Corning, Catalog No. 3764), with 20 μL of cells per well, i.e., 2000 to 4000 cells per well. 20 μL of hybridoma supernatant was added to all wells of the 384-well plate, except for the positive and negative control wells. The plate was incubated at room temperature in the dark for 2 hours before being read on a Mirrorball instrument (Sptlabtech).

[0727] Table 4. Hybridoma supernatant mirrorball assay results Note: “+” indicates binding, “-” indicates no binding.

[0728] 3. Screening of MUC1-C antibodies based on hybridoma cells

[0729] Four hybridomas obtained after ELISA and mirrorball qualitative testing were sequenced, and the corresponding antibodies were named after sequencing. The antibody from hybridoma 17F3 was named M4, the antibody from hybridoma 28E4 was named M6, the antibody from hybridoma 3H6 was named F4-1, and the antibody from hybridoma 36G9 was named F4-18.

[0730] The four antibodies obtained were sequenced and the resulting sequences were classified by CDR. The mouse variable region sequences were selected and connected to the human antibody constant region sequences to express chimeric antibodies. The amino acid sequences of the heavy and light chain variable regions of the screened antibodies are as follows:

[0731] Note: In the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The underlined part is the CDR sequence determined according to the Kabat numbering system, and the non-underlined part is the FR sequence.

[0732] The heavy chain and light chain CDR region sequences of the murine antibodies M4, M6, F4-1 and F4-18 are shown in the following table:

[0733] Table 5. Antibody heavy chain and light chain CDR sequences Note: The CDRs in the table are determined according to the Kabat numbering system.

[0734] Example 5: Humanization of anti-MUCl-C murine antibody

[0735] Using MOE software, we compared the heavy and light chain variable region germline genes with high homology to M4, M6, F4-1, and F4-18 using the IMGT human antibody heavy and light chain variable region germline genes. We selected these four murine CDRs as templates and transplanted them into the corresponding human templates, creating a variable region sequence with the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. For example, the CDR amino acid residues in the following specific examples are identified and annotated using the Kabat numbering system.

[0736] 1. Humanization of M4 mouse antibody

[0737] The humanized light chain templates for the murine antibody M4 are IGKV1-39*01 / IGKV6-21*02 / IGKV3-11*01 and IGKJ4*01, and the humanized heavy chain templates are IGHV1-46*01 and IGHJ6*01. The CDRs of the murine antibody M4 were transplanted into their humanized templates, and the FRs of the humanized antibody were then backmutated. These modifications were designed to remove potential chemical modifications such as isomerization, eliminate N-terminal pyroglutamate formation, and reduce potential immunogenicity. The light chain FRs include one or more mutations in 3, 43, 47, 49, or 60 (the positions of these mutations are determined according to the Kabat numbering convention), and the heavy chain FRs include one or more mutations in 1, 28, 38, 40, 48, 71, 73, 76, or 82a (the positions of these mutations are determined according to the Kabat numbering convention). The amino acid substitutions in the humanized variable regions of antibody M4 are shown in the table below.

[0738] Table 6. Amino acid substitutions in the variable region of the M4 humanized antibody Note: Graft represents the implantation of murine antibody CDRs into human germline FR regions; the position of the mutation site is determined according to the Kabat numbering convention, e.g., "S82aR" indicates that the S at position 82a (also known as 82A) is mutated to R according to the Kabat numbering system.

[0739] The sequences of the heavy chain variable region and light chain variable region of the M4 humanized antibody are as follows:

[0740] Among them, in the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the underlined part in the sequence is the CDR sequence determined according to the Kabat numbering system, and the non-underlined part is the FR sequence.

[0741] 2. Humanization of M6 mouse antibody

[0742] The humanized light chain templates for the murine antibody M6 are IGKV4-1*01 / IGKV3-11*01 and IGKJ4*01, and the humanized heavy chain templates are IGHV1-46*01 and IGHJ6*01. The CDRs of the murine antibody M6 were transplanted into their humanized templates, and the FRs of the humanized antibody were then backmutated. This took into account the removal of potential chemical modification sites such as isomerization, the formation of N-terminal pyroglutamate, and the reduction of potential immunogenicity. The light chain FRs include one or more mutations in 1, 4, 45, 68, or 83 (the positions of the mutation sites are determined according to the Kabat numbering convention), and the heavy chain includes one or more mutations in 1, 28, 30, 39, 40, 43, 69, 71, 76, 82b, 83, 84, and 97 (the positions of the mutation sites are determined according to the Kabat numbering convention). The amino acid substitutions in the variable regions of the humanized antibody M6 are shown in the table below.

[0743] Table 7-1. Amino acid substitutions in the variable region of the M6 ​​humanized antibody Note: Graft represents the implantation of murine antibody CDRs into human germline FRs. The position of the mutation site is determined according to the Kabat numbering convention, e.g., "G68R" indicates that the G at position 68 is mutated to R according to the Kabat numbering system.

[0744] The sequences of the heavy chain variable region and light chain variable region of the M6 ​​humanized antibody are as follows:

[0745] The CDRs of the M6 ​​humanized antibody are as follows:

[0746] Table 7-2. CDRs of M6 humanized antibody

[0747] Among them, in the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the underlined part is the CDR sequence determined according to the Kabat numbering system, and the non-underlined part is the FR sequence.

[0748] 3. Humanization of F4-1 mouse antibody

[0749] The humanized light chain templates for the murine antibody F4-1 are IGKV1-39*01 and IGKJ4*01, and the humanized heavy chain templates are IGHV1-3*01 and IGHJ6*01. The CDRs of the murine antibody F4-1 were transplanted into their humanized templates. The FRs of the humanized antibody were then backmutated to remove potential chemical modification sites such as isomerization, the formation of N-terminal pyroglutamate, and to reduce potential immunogenicity. The light chain FRs include mutations at positions 4, 36, 42, 43, 47, 60, 70, and 75 (the positions of the mutations are determined according to the Kabat numbering convention), and the heavy chain FRs include one or more mutations at positions 1, 2, 12, 40, 44, 47, 48, 69, 71, and 76 (the positions of the mutations are determined according to the Kabat numbering convention). The amino acid substitutions in the humanized variable regions of antibody F4-1 are shown in the table below.

[0750] Table 8. Amino acid substitutions in the variable region of the F4-1 humanized antibody Note: Graft represents the implantation of murine antibody CDRs into human germline FR regions; the position of the mutation site is determined according to the Kabat numbering convention. For example, "Y36F" indicates that the Y at position 36 has been mutated to an F according to the Kabat numbering convention.

[0751] The sequences of the heavy chain variable region and light chain variable region of the F4-1 humanized antibody are as follows:

[0752] Among them, in the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the underlined part is the CDR sequence determined according to the Kabat numbering system, and the non-underlined part is the FR sequence.

[0753] 4. Humanization of F4-18 mouse antibody

[0754] The humanized light chain templates for the murine antibody F4-18 are IGKV1-39*01 and IGKJ4*01, and the humanized heavy chain templates are IGHV1-3*01 and IGHJ1*01. The CDRs of the murine antibody F4-18 were transplanted into their humanized templates. The FRs of the humanized antibody were then backmutated to remove potential chemical modification sites such as isomerization, the formation of N-terminal pyroglutamate, and to reduce potential immunogenicity. The light chain FRs include mutations at 4, 36, 39, 42, 44, 46, 60, 66, 69, and 71 (the positions of the mutations are determined according to the Kabat numbering convention), while the heavy chain includes one or more mutations at 12, 20, 24, 40, 44, 48, 69, 71, 96, and 101 (the positions of the mutations are determined according to the Kabat numbering convention). The amino acid substitutions in the humanized variable regions of antibody F4-18 are shown in the table below.

[0755] Table 9-1. Amino acid substitutions in the variable region of the F4-18 humanized antibody Note: Graft represents the implantation of murine antibody CDRs into human germline FRs; the position of the mutation site is determined according to the Kabat numbering convention. For example, "M4L" indicates that the fourth position, M, was mutated to L according to the Kabat numbering convention.

[0756] The sequences of the heavy chain variable region and light chain variable region of the F4-18 humanized antibody are as follows:

[0757] The CDRs of the F4-18 humanized antibody are as follows:

[0758] Table 9-2. CDRs of F4-18 humanized antibody

[0759] Among them, in the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the underlined part is the CDR sequence determined according to the Kabat numbering system, and the non-underlined part is the FR sequence.

[0760] 5. Construction and expression of anti-MUC1-C humanized antibody IgG1

[0761] Primers were designed and PCR was used to construct each humanized antibody VH / VK gene fragment, which was then homologously recombined with the expression vector pTT5 (with a signal peptide and constant region gene (CH1-FC / CL) fragment, constructed in the laboratory) to construct the full-length antibody expression vector VH-CH1-FC-pTT5 / VK-CL-pTT5. The heavy chain constant region of the antibody can be selected from the heavy chain constant region of human IgG1, IgG2, IgG3, IgG4, or variants thereof, and the light chain constant region can be selected from the light chain constant region of human κ, λ chain, or variants thereof. Exemplarily, in the following examples, the antibody heavy chain constant region is selected from the human IgG1 heavy chain constant region set forth in SEQ ID NO: 69 or 186, and the light chain constant region is selected from the human light chain constant region set forth in SEQ ID NO: 70.

[0762] Human IgG1 heavy chain constant region sequence:

[0763] Human IgG1 heavy chain constant region sequence (with LALA mutation):

[0764] Human light chain constant region sequence:

[0765] The carboxyl terminus of the heavy chain variable region of the previously screened murine antibodies M4, M6, F4-1, and F4-18 was linked to the amino terminus of the human heavy chain constant region as shown in SEQ ID NO: 69, and the carboxyl terminus of the light chain variable region of the murine antibody was linked to the amino terminus of the human light chain constant region as shown in SEQ ID NO: 70 to obtain the corresponding chimeric antibodies. Specifically, the chimeric antibodies of M4, M6, F4-1, and F4-18 are represented as ChiM4, ChiM6, ChiF4-1, and ChiF4-18, respectively.

[0766] The carboxyl terminus of the heavy chain variable region of the previously constructed humanized antibodies M4, M6, F4-1, and F4-18 was linked to the amino terminus of the human heavy chain constant region as shown in SEQ ID NO: 69 to form a full-length heavy chain of the antibody. The carboxyl terminus of the light chain variable region of the humanized antibodies M4, M6, F4-1, and F4-18 was linked to the amino terminus of the human light chain constant region as shown in SEQ ID NO: 70 to form a full-length light chain of the antibody. The humanized antibodies shown in Tables 10 to 13 below can be obtained.

[0767] Table 10. Humanized antibodies of M4 Note: "M4-H1L1" in the table indicates a humanized antibody whose heavy chain variable region is huM4VH1 (SEQ ID NO: 36), whose light chain variable region is huM4VL1 (SEQ ID NO: 39), whose heavy chain constant region is as shown in SEQ ID NO: 69, and whose light chain constant region is as shown in SEQ ID NO: 70, and so on.

[0768] Table 11. Humanized antibodies of M6 Note: "M6-H1L1" in the table indicates a humanized antibody whose heavy chain variable region is huM6VH1 (SEQ ID NO: 43), whose light chain variable region is huM6VL1 (SEQ ID NO: 50), whose heavy chain constant region is as shown in SEQ ID NO: 69, and whose light chain constant region is as shown in SEQ ID NO: 70, and so on.

[0769] Table 12. Humanized antibodies of F4-1 Note: "F4-1-H1L1" in the table indicates a humanized antibody whose heavy chain variable region is huF4-1VH1 (SEQ ID NO: 53), whose light chain variable region is huF4-1VL1 (SEQ ID NO: 56), whose heavy chain constant region is as shown in SEQ ID NO: 69, and whose light chain constant region is as shown in SEQ ID NO: 70, and so on.

[0770] Table 13. Humanized antibodies of F4-18 Note: "F4-18-H1L1" in the table indicates a humanized antibody whose heavy chain variable region is huF4-18VH1 (SEQ ID NO: 60), whose light chain variable region is huF4-18VL1 (SEQ ID NO: 65), whose heavy chain constant region is as shown in SEQ ID NO: 69, and whose light chain constant region is as shown in SEQ ID NO: 70, and so on.

[0771] Exemplary full-length sequences of humanized antibody heavy and light chains are as follows:

[0772] Note: In the above antibody full-length sequence, the underlined part is the antibody variable region sequence, and the non-underlined part is the antibody constant region sequence.

[0773] Example 6: Modification of anti-EGFR antibodies

[0774] The molecule that specifically binds to EGFR can be derived from any suitable antibody, such as Zalutumumab or a variant thereof, wherein:

[0775] Table 14. CDR sequences of Zalutumumab

[0776] By mutating amino acids at positions 31, 33, 52A, 56, 60, 97, and / or 99 of the heavy chain variable region of Zalutumumab, and / or mutating amino acid position 1 of the light chain variable region, a total of 15 anti-EGFR antibodies were obtained, namely: ZalH', ZalH1, ZalH2, ZalH3, ZalH4, ZalH5, ZalH6, ZalH7, ZalH8, ZalH9, ZalH10, ZalH11, ZalH12, ZalH13, and ZalH14. The specific sequences are as follows:

[0777] Table 15. Amino acid sequences of replaced CDRs Note: Antibody ZalH1 indicates amino acid mutations at position 31 (i.e., HCDR1) and position 1 of the heavy chain variable region of zalutumumab; antibody ZalH7 indicates mutations at positions 31 and 52A (i.e., HCDR1 and HCDR2) of the heavy chain variable region and position 1 of the light chain variable region of zalutumumab; ZalH' indicates mutations only at position 1 of the light chain variable region of zalutumumab; the heavy chain constant region of the antibody is selected from the human IgG1 heavy chain constant region set forth in SEQ ID NO: 69, and the light chain constant region is selected from the human light chain constant region set forth in SEQ ID NO: 70. The same applies to other antibodies.

[0778] Note: In the above antibody sequences, the underlined part is the antibody variable region sequence, the double underlined part is the antibody CDR sequence, the non-underlined part is the antibody constant region sequence, and the bold letters are the mutated amino acids.

[0779] Example 7: Construction of anti-EGFR-MUC1 dual antibody

[0780] The EGFR-MUC1 bispecific antibody adopts a 1:1 molecular format. The MUC1 arm is selected as M4-H1L1 (hereinafter referred to as "M4H1L1") and is assembled with EGFR antibodies ZalH', ZalH4, ZalH8, ZalH10, and ZalH13, respectively. The VH of the EGFR antibody is combined with titin, and the VL is combined with obscurin. In addition, S358C and T370W mutations (knob) are introduced into the MUC1 antibody heavy chain, and Y357C, T374S, L376A, and Y415V mutations (hole) are introduced into the EGFR antibody heavy chain. The format is an asymmetric structure molecule containing four chains:

[0781] Chain 1: [VH(anti-MUC1)]-[IgG1(CH1)]-[Fc(Knob)];

[0782] Chain 2: [VL(anti-MUC1)]-[CL];

[0783] Chain 3: [VH(anti-EGFR)]-[Linker 1]-[Titin]-[Fc(Hole)];

[0784] Chain 4: [VL (anti-EGFR)]-[Linker 2]-[Obscurin], a schematic diagram of which is shown in FIG5 (wherein: T represents titin, and O represents obscurin).

[0785] Table 16. Bispecific antibodies of the present disclosure Note: For example, M4H1L1-ZalH' indicates that the molecule uses the variable region of M4-H1L1 as the MUC1 binding domain, the variable region of ZalH' as the EGFR binding domain, and the Format shown in Figure 5 as the molecular structure, and so on.

[0786] Note: In the above antibody sequences, the underlined part is the antibody variable region sequence, the non-underlined part is the antibody constant region sequence, and the wavy underline is the linker sequence.

[0787] The VH / VL sequences of the negative control antibody IgG1 used in this disclosure are from patent US6114143A, and the heavy chain constant region and light chain constant region sequences are SEQ ID NO: 69 and SEQ ID NO: 70, respectively. The full-length sequences are as follows:

[0788] Note: The underlined part in the sequence is the variable region, and the italic part is the constant region.

[0789] Example 8: M4H1L1-ZalH4-LALA dual antibody

[0790] The M4H1L1-ZalH4-LALA bispecific antibody is based on the M4H1L1-ZalH4 bispecific antibody. L238A and L239A mutations are introduced into chain 1, and L242A and L243A mutations are introduced into chain 3. The sequences of chains 2 and 4 remain unchanged. M4H1L1-ZalH4-LALA is obtained. It contains four chains. The specific sequences are as follows:

[0791] Note: In the above antibody sequences, the underlined part is the antibody variable region sequence, the non-underlined part is the antibody constant region sequence, the wavy underline is the linker sequence, and the bold letters are the mutated amino acids.

[0792] Example 9: EGFR-MUC1 dual antibody coupled with M toxin

[0793] M4H1L1-ZalH'-M

[0794] To a solution of antibody M4H1L1-ZalH' in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 0.38 mL, 25.7 nmol) at 37°C was added a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 6.3 μL, 63 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to terminate the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL. Compound M (0.245 mg, 257 nmol) was dissolved in 24 μL of acetonitrile and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (eluting phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain M4H1L1-ZalH'-M in histidine-acetate buffer (0.3 mg / mL, 10.2 mL). The product was stored refrigerated at 4°C. The average DAR calculated by MS was n = 3.87.

[0795] M4H1L1-ZalH4-M

[0796] At 37°C, a solution of antibody M4H1L1-ZalH4 in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 0.5 mL, 33.8 nmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 8.4 μL, 84 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to terminate the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0797] Compound M (0.32 mg, 338 nmol) was dissolved in 32 μL of acetonitrile and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (eluting phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain M4H1L1-ZalH4-M in histidine-acetate buffer (0.42 mg / mL, 10.7 mL). The mixture was stored refrigerated at 4°C. The average DAR calculated by MS was n = 4.8.

[0798] M4H1L1-ZalH8-M

[0799] At 37°C, a solution of antibody M4H1L1-ZalH8 in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 0.5 mL, 33.8 nmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 8.25 μL, 82.5 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0800] Compound M (0.32 mg, 338 nmol) was dissolved in 32 μL of acetonitrile and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (eluting phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain M4H1L1-ZalH8-M in histidine-acetate buffer (0.39 mg / mL, 10.7 mL). The mixture was stored refrigerated at 4°C. The average DAR calculated by MS was n = 4.13.

[0801] M4H1L1-ZalH10-M

[0802] At 37°C, a solution of antibody M4H1L1-ZalH10 in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 0.276 mL, 18.6 nmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 4.57 μL, 45.7 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to terminate the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0803] Compound M (0.18 mg, 186 nmol) was dissolved in 18 μL of acetonitrile and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (eluting phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain the title product, M4H1L1-ZalH10-M, in histidine-acetate buffer (0.22 mg / mL, 10.2 mL). The product was stored refrigerated at 4°C. The average DAR calculated by MS was n = 4.33.

[0804] M4H1L1-ZalH13-M

[0805] At 37°C, a solution of antibody M4H1L1-ZalH13 in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 0.47 mL, 32 nmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 7.85 μL, 78.5 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to terminate the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0806] Compound M (0.306 mg, 320 nmol) was dissolved in 31 μL of acetonitrile and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (eluting phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain M4H1L1-ZalH13-M in histidine-acetate buffer (0.42 mg / mL, 10.2 mL). The mixture was stored refrigerated at 4°C. The average DAR calculated by MS was n = 4.3.

[0807] IgG1-M

[0808] To an IgG1 antibody solution in PBS buffer (pH 6.3, 0.05 M PBS buffer; 10.0 mg / mL, 0.5 mL, 33.8 nmol) at 37°C was added a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 8.11 μL, 81.1 nmol). The solution was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath.

[0809] Compound M (0.32 mg, 338 nmol) was dissolved in 32 μL of acetonitrile and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (elution phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain IgG1-M in histidine-acetate buffer (0.48 mg / mL, 10.2 mL). The mixture was then refrigerated and stored at 4°C. The average DAR calculated by MS was n = 4.37.

[0810] Example 10: Antibody conjugated to 9-A toxin

[0811] 1.EGFR-MUC1 dual antibody conjugated to 9-A toxin

[0812] ADC-1

[0813] At 37°C, a solution of antibody M4H1L1-ZalH4 in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 30 mL, 2.027 μmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 851 μL, 8.51 μmol). The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0814] Compound 9-A (26.1 mg, 24.32 μmol) was dissolved in 1.5 mL of dimethyl sulfoxide and added dropwise to the above reaction solution. The mixture was placed in a water bath shaker and shaken at 25°C for 3 hours to stop the reaction. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: pH 5.0 30 mM histidine-acetate buffer) to obtain ADC-1 in histidine-acetate buffer (7.1 mg / mL, 39 mL), which was refrigerated and stored at 4°C. HIC calculation of DAR

[0815] Average value: n = 5.78. ADC-2

[0816] At 37°C, a solution of antibody M4H1L1-ZalH4 in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 30.8 mL, 2.074 μmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 509.5 μL, 5.095 μmol). The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0817] Compound 9-A (22.3 mg, 20.74 μmol) was dissolved in 1.5 mL of dimethyl sulfoxide and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (elution phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain ADC-2 in histidine-acetate buffer (5.8 mg / mL, 47.6 mL). The mixture was then refrigerated and stored at 4°C. The average DAR value calculated by HIC was n = 4.5.

[0818] ADC-3

[0819] At 37°C, a solution of antibody M4H1L1-ZalH4-LALA in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 1.11 mL, 75 nmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 29.3 μL, 293 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0820] Compound 9-A (0.967 mg, 900 nmol) was dissolved in 55 μL of dimethyl sulfoxide and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (elution phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain ADC-3 in histidine-acetate buffer (0.96 mg / mL, 10.5 mL). The mixture was then refrigerated and stored at 4°C. The average DAR calculated by MS was n = 5.51.

[0821] 2.EGFR antibody conjugated to 9-A toxin

[0822] ZalH4-9-A

[0823] At 37°C, a solution of antibody ZalH4 in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 1.57 mL, 106 nmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 35 μL, 350 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0824] Compound 9-A (1.37 mg, 1.272 μmol) was dissolved in 80 μL of dimethyl sulfoxide and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (elution phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain ZalH4-9-A in histidine-acetate buffer (1.1 mg / mL, 12.8 mL). The mixture was stored refrigerated at 4°C. The average DAR calculated by RP-HPLC was n = 5.94.

[0825] 3.MUC1 antibody conjugated to 9-A toxin

[0826] M4H1L1-9-A

[0827] At 37°C, a solution of antibody M4H1L1 in PBS buffer (0.05 M PBS buffer, pH 6.3; 10.0 mg / mL, 1.4 mL, 94.6 nmol) was added with a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 31.2 μL, 312 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath and then exchanged with 30 mM histidine-acetate buffer, pH 5.0, using a Sephadex G25 gel column and concentrated to 10 mg / mL.

[0828] Compound 9-A (1.22 mg, 1.135 μmol) was dissolved in 70 μL of dimethyl sulfoxide and added dropwise to the reaction mixture. The mixture was shaken in a water bath at 25°C for 3 hours, after which the reaction was stopped. The reaction mixture was desalted and purified using a Sephadex G25 gel column (elution phase: 30 mM histidine-acetate buffer, pH 5.0) to obtain M4H1L1-9-A in histidine-acetate buffer (0.94 mg / mL, 12.5 mL). The product was stored refrigerated at 4°C. RP-HPLC calculated average: n = 6.6.

[0829] 4. Negative control antibody conjugated to 9-A toxin

[0830] IgG1-9-A

[0831] To an IgG1 antibody solution in PBS buffer (pH 6.3, 0.05 M PBS buffer; 10.0 mg / mL, 3.9 mL, 263 nmol) was added a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 81.6 μL, 816 nmol) at 37°C. The mixture was shaken in a water bath at 37°C for 3 hours to terminate the reaction. The reaction solution was cooled to 25°C in a water bath.

[0832] Compound 9-A (3.4 mg, 3.162 μmol) was dissolved in 200 μL of dimethyl sulfoxide and added dropwise to the above reaction solution. The mixture was placed in a water bath shaker and shaken at 25°C for 3 hours, after which the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: 0.05 M PBS buffer solution at pH 6.3, containing 0.001 M EDTA) to obtain the title product, IgG-9-A, in PBS buffer (2.42 mg / mL, 14.7 mL). The product was stored refrigerated at 4°C. RP-HPLC calculated average: n = 6.15.

[0833] Test Example 1: FACS-based determination of chimeric antibody affinity

[0834] HCC827-human-MUC1-C (in-house constructed overexpression stable cell line), CHOK1-cyno-MUC1-C (in-house constructed overexpression stable cell line) and T47D cells (human ductal breast cancer cells) were digested separately and added to 96-well plates at 1E5 cells per well. After centrifugation at 300g for 5 minutes, the supernatant was discarded and the cells were washed once with PBS buffer containing 2% FBS. The antibody was diluted 5-fold in PBS buffer with 2% FBS at a starting concentration of 20μg / mL, with a total of 8 concentration gradients. 100 microliters of antibody sample was added to each well, the cells were resuspended and incubated at 4°C for 1 hour. After centrifugation at 300g for 5 minutes, the supernatant was discarded and the cells were washed twice with PBS buffer containing 2% FBS. Secondary antibody (Alexa Cells were incubated with 488 goat anti-human IgG (H+L) (1:1000, Invitrogen, A11013) at 4°C for 40 minutes. After centrifugation at 300g for 5 minutes, the supernatant was discarded and the cells were washed twice with PBS containing 2% FBS. Cells were resuspended in 100 μL of PBS containing 2% FBS and analyzed by FACS. The results of the FACS analysis are shown below.

[0835] Table 17. Results of the affinity test between chimeric antibodies and cells based on FACS

[0836] The results showed that the chimeric antibody disclosed herein has a strong affinity with stably transfected cell lines or tumor cell lines.

[0837] Test Example 2: Tumor Cell Internalization Test of Anti-MUC1-C Chimeric Antibody

[0838] 1. Test Purpose

[0839] The purpose of this experiment is to detect the endocytic activity of MUC1 chimeric monoclonal antibody drugs on tumor cells. Cells were treated with different concentrations of MUC1 chimeric monoclonal antibody drugs in vitro and cultured for 3 days. Luminescent Cell Viability Assay (Promega, Catalog No. G7573) was used to detect the proliferation of tumor cells. 50 The endocytic activity of the antibody was evaluated.

[0840] 2. Experimental Methods

[0841] The following uses the in vitro proliferation inhibition test method of T47D cells as an example to illustrate the method for testing the endocytosis activity of the disclosed MUC1 chimeric monoclonal antibody drug on tumor cells. This method is also applicable to, but not limited to, testing the in vitro proliferation inhibition activity of other tumor cells.

[0842] 1. Cell culture: T47D cells were cultured in 1640 medium (GE, Catalog No. SH30024.01) supplemented with 10% FBS and 2 μg / mL human insulin (Yisheng, Catalog No. 40112ES60).

[0843] 2. Cell preparation: Take T47D cells in the logarithmic growth phase, wash once with PBS (phosphate buffered saline, Shanghai Yuanpei Biotechnology Co., Ltd.), add 2-3 mL of trypsin (0.25% Trypsin-EDTA (1x), Gibco, Life Technologies) and digest for 2-3 minutes. After the cells are completely digested, add 10-15 mL of cell culture medium to elute the digested cells, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, and then add 10-20 mL of cell culture medium containing 20% ​​ultra-low IgG fetal bovine serum (Bosheng Bio, product number BS-0007-500) to resuspend the cells to make a single-cell suspension.

[0844] 3. Cell plating: Mix the T47D single cell suspension and adjust the viable cell density to 4×10 4cells / mL. Mix the density-adjusted cell suspension and add 50 μL / well to a 96-well cell culture plate. Add only 100 μL of culture medium to the outer wells of the 96-well plate. Incubate the plate in an incubator (37°C, 5% CO2) for 24 hours.

[0845] 4. Preparation of MUC1 chimeric monoclonal antibody: Prepare DT3C (a fusion of diphtheria toxin fragment A and group G Streptococcus 3C fragment) at a concentration of × in serum-free RPMI 1640 medium, at a molar concentration 6 times that of the antibody. Prepare the antibody at a 4× concentration in the same medium. Mix DT3C and antibody at a 1:1 ratio by volume and incubate at room temperature for 30 minutes. Then, perform serial dilutions.

[0846] 5. Sample addition: Add the diluted antibody to the cells at a 1:1 ratio, 50 μL / well. Repeat for each sample in duplicate. Incubate the plate in an incubator for 3 days (37°C, 5% CO2).

[0847] 6. Color development: Take out the 96-well cell culture plate, add 50 μL CTG solution to each well, and incubate at room temperature for 10 minutes.

[0848] 7. Plate reading operation: Take out the 96-well cell culture plate, place it in a microplate reader (PE, Envision), and measure the chemiluminescence using the microplate reader.

[0849] 3. Data Analysis

[0850] The data were processed and analyzed using Microsoft Excel and Graphpad Prism 5. The results of the embodiment are shown in the following table and Figures 1 and 2.

[0851] Table 18-1. In vitro internalization experiment of MUC1-C chimeric antibody on T47D cells

[0852] Table 18-2. In vitro internalization experiment of MUC1-C chimeric antibody on T47D cells

[0853] The results showed that the chimeric antibody disclosed herein has strong endocytic activity against T47D tumor cell line.

[0854] Test Example 3: FACS evaluation of chimeric and humanized antibodies

[0855] The experimental procedure was the same as in Test Example 1, "FACS-based Affinity Determination of Chimeric Antibodies." Additionally, CHOK1-human-MUC1-C cells (an internally constructed stably overexpressing cell line) were used for evaluation. The results are shown in the table below and Figures 3A to 3P.

[0856] Table 19-1. FACS results of chimeric and humanized antibodies Note: “+” indicates a combination.

[0857] Table 19-2. FACS results of chimeric and humanized antibodies Note: “+” indicates a combination.

[0858] Table 19-3. FACS results of chimeric and humanized antibodies Note: “+” indicates a combination.

[0859] Table 19-4. FACS results of chimeric and humanized antibodies Note: “+” indicates a combination.

[0860] The results showed that the chimeric antibodies and humanized antibodies disclosed herein had different affinities with stably transfected cell lines or tumor cell lines, and both had human-monkey cross-binding activity.

[0861] Test Example 4: Tumor Cell Internalization Test of Anti-MUC1-C Humanized Antibody

[0862] 1. Test Purpose

[0863] The purpose of this experiment is to detect the endocytic activity of MUC1 humanized monoclonal antibody drugs on tumor cells. Cells were treated with different concentrations of MUC1 humanized monoclonal antibody drugs in vitro, and after 3 days of culture, CTG ( Luminescent Cell Viability Assay (Promega, Catalog No. G7573) was used to detect the proliferation of tumor cells. 50 The endocytic activity of the antibody was evaluated.

[0864] 2. Experimental Methods

[0865] The following uses the in vitro proliferation inhibition test method of T47D cells as an example to illustrate the method for testing the endocytosis activity of the disclosed MUC1 humanized monoclonal antibody drug on tumor cells. This method is also applicable to, but not limited to, testing the in vitro proliferation inhibition activity of other tumor cells.

[0866] 1. Cell culture: T47D cells were cultured in 1640 medium (GE, Catalog No. SH30024.01) supplemented with 10% FBS and 2 μg / mL human insulin (Yisheng, Catalog No. 40112ES60).

[0867] 2. Cell preparation: Take T47D cells in the logarithmic growth phase, wash once with PBS (phosphate buffered saline, Shanghai Yuanpei Biotechnology Co., Ltd.), add 2-3 mL of trypsin (0.25% Trypsin-EDTA (1x), Gibco, Life Technologies) and digest for 2-3 minutes. After the cells are completely digested, add 10-15 mL of cell culture medium to elute the digested cells, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, and then add 10-20 mL of cell culture medium containing 20% ​​ultra-low IgG fetal bovine serum (Bosheng Bio, product number BS-0007-500) to resuspend the cells to make a single-cell suspension.

[0868] 3. Cell plating: Mix the T47D single cell suspension and adjust the viable cell density to 4×10 4 cells / mL. Mix the density-adjusted cell suspension and add 50 μL / well to a 96-well cell culture plate. Add only 100 μL of culture medium to the outer wells of the 96-well plate. Incubate the plate in an incubator (37°C, 5% CO2) for 24 hours.

[0869] 4. Preparation of MUC1 chimeric monoclonal antibody: Prepare DT3C (a fusion of diphtheria toxin fragment A and group G Streptococcus 3C fragment) at a 4X concentration in serum-free RPMI 1640 medium. Prepare the antibody at a 4X concentration in the same medium. Mix DT3C and antibody at a 1:1 ratio by volume and incubate at room temperature for 30 minutes. Then, perform serial dilutions.

[0870] 5. Sample addition: Add the diluted antibody to the cells at a 1:1 ratio, 50 μL / well. Repeat for each sample in duplicate. Incubate the plate in an incubator for 3 days (37°C, 5% CO2).

[0871] 6. Color development: Take out the 96-well cell culture plate, add 50 μL CTG solution to each well, and incubate at room temperature for 10 minutes.

[0872] 7. Plate reading operation: Take out the 96-well cell culture plate, place it in a microplate reader (PE, Envision), and measure the chemiluminescence using the microplate reader.

[0873] 3. Data Analysis

[0874] The data were processed and analyzed using Microsoft Excel and Graphpad Prism 5. The results of the embodiment are shown in Table 20 and Figures 4A to 4F.

[0875] Table 20. In vitro internalization experiment of MUC1-C humanized antibody on T47D cells

[0876] The results showed that the humanized antibody disclosed herein has strong endocytosis activity against T47D tumor cell line. Test Example 5: Biacore detection of anti-MUC1-C antibody affinity experiment

[0877] 1. Test instruments: Biacore 8K, Cytiva

[0878] 2. Test materials: Protein A biosensor chip (Cat.#29127556, Cytiva)

[0879] 3. Test reagents:

[0880] 1) 10 x HBS-EP+ buffer solution (pH 7.4) (Cat.# BR-1006-69, Cytiva)

[0881] 2) 10mM Glycine-HCl (pH 1.5) (Cat.#BR-1003-54, Cytiva)

[0882] 3)MUC1-CL-His (homemade)

[0883] 4) Antibody sample to be tested (self-made)

[0884] The affinity of the disclosed antibodies to human MUCl-CL-His antigen was tested using a Biacore 8K instrument.

[0885] The method is as follows: Antibody molecules were affinity-captured using a Protein A biosensor chip. A specific concentration of antigen was then passed over the chip surface. Sample injection was continued for 180 seconds, followed by a 600-second natural dissociation period. Binding and dissociation curves were obtained using a Biacore 8K instrument. After each dissociation cycle, the biosensor chip was washed and regenerated with 10 mM Glycine-HCl (pH 1.5). The Kinetics 1:1 binding model was used for data fitting. The results are shown in Table 21.

[0886] Table 21. Affinity test results of anti-MUC1 antibodies to human MUC1 antigen

[0887] The results showed that the anti-MUCl-C antibodies disclosed herein have high affinity for human MUCl-C antigen.

[0888] Test Example 6: Biacore detection of anti-EGFR antibody affinity experiment

[0889] 1. Test instruments: Biacore 8K, Cytiva

[0890] 2. Test materials: Protein A biosensor chip (Cat.#29127556, Cytiva)

[0891] 3. Test reagents:

[0892] 1) 10 x HBS-EP+ buffer solution (pH 7.4) (Cat.# BR-1006-69, Cytiva)

[0893] 2)10mM Glycine-HCl (pH 1.5)(Cat.#BR-1003-54,Cytiva)

[0894] 3) EGFR-His (homemade)

[0895] 4) Antibody sample to be tested (self-made)

[0896] The affinity of the disclosed antibodies to human EGFR-His antigen was tested using a Biacore 8K instrument.

[0897] The method is as follows: Antibody molecules were affinity-captured using a Protein A biosensor chip. A specific concentration of antigen molecules was then passed over the...

Claims

1. An anti-MUC1 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein: a. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 4, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 5; or b. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 of any one of SEQ ID NO: 6 or 47, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 of SEQ ID NO: 7; or c. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 8, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 9; or d. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 of any one of SEQ ID NO: 63, 10 or 64, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 of SEQ ID NO: 11; Preferably, a. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 4, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 5; or b. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 6, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 7; or c. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 8, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 9; or d. the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 63, and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 11, respectively; More preferably, the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region respectively comprise the amino acid sequences of HCDR1, HCDR2 and HCDR3 in SEQ ID NO:4, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region respectively comprise the amino acid sequences of LCDR1, LCDR2 and LCDR3 in SEQ ID NO:

5.

2. The anti-MUC1 antibody or antigen-binding fragment thereof according to claim 1, wherein: a. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; or b. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 18, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 19, and the HCDR3 comprises the amino acid sequence of any one of SEQ ID NO: 20 or 113, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 21, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 22, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 23; or c. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 25, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 26, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 27, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 28, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 29; or d. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 31, and the HCDR3 comprises the amino acid sequence of any one of SEQ ID NO: 114, 32 or 115, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 34, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 35; Preferably, a. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; b. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 18, HCDR2 comprises the amino acid sequence of SEQ ID NO: 19, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 20, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 21, LCDR2 comprises comprising the amino acid sequence of SEQ ID NO: 22, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 23; or c. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 25, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 26, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 27, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 28, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 29; or d. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 31, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 114, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 34, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 35; More preferably, HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 15, LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and LCDR3 comprises the amino acid sequence of SEQ ID NO:

17.

3. The anti-MUC1 antibody or antigen-binding fragment thereof according to claim 1 or 2, which is a murine antibody, a chimeric antibody, a humanized antibody or a fully human antibody; preferably a chimeric antibody or a humanized antibody; more preferably a humanized antibody.

4. The anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein: a. the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 36, 37 or 38, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 39, 40, 41 or 42; or the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 4, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 5; or b. the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 43, 44, 45, 46, 47, 48 or 49, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 50, 51 or 52; or the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 6, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 7; or c. the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 53, 54 or 55, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 56, 57, 58 or 59. or the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 8, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 9; or d. the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 63, 60, 61, 62 or 64, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 67, 68, 65 or 66; or the heavy chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 10, and the light chain variable region comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 11; Preferably, a. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39 or 40; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 37, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39 or 40; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 5; b. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 43, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 50; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 44, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 51; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 45, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 50 or 51; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 46, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 51; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 6, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 7; c. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 53, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 56, 57 or 59; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 54, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 57; or or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 8, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 9; d. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 60, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 65 or 68; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 61, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 65, 66, 67 or 68; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63, and the light chain variable region comprises The amino acid sequence of SEQ ID NO: 67 or 68; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 10, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 11; More preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:

39.

5. The anti-MUCl antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, which is an antibody fragment; preferably, it is selected from the group consisting of: Fab, Fab', F(ab')2, Fd, Fv, scFv, dsFv and dAb.

6. The anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the anti-MUC1 antibody comprises a heavy chain constant region and a light chain constant region; Preferably, the heavy chain constant region is a human IgG1, IgG2, IgG3 or IgG4 heavy chain constant region, The light chain constant region is a human kappa or lambda light chain constant region; More preferably, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 69 or 186, The light chain constant region comprises the amino acid sequence of SEQ ID NO:

70.

7. The anti-MUC1 antibody or antigen-binding fragment thereof according to claim 6, wherein the anti-MUC1 antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain, wherein: a. the heavy chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 71, 73, 75 or 77, and the light chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 72, 74, 76 or 78; or b. the heavy chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 79, 81, 83, 85 or 87, and the light chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 80, 82, 84, 86 or 88; or c. the heavy chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 89, 91, 93 or 95, and the light chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 90, 92, 94 or 96; or d. the heavy chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109 or 111, and the light chain comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110 or 112; Preferably, a. the amino acid sequence of the heavy chain is shown in SEQ ID NO: 71, and the amino acid sequence of the light chain is shown in SEQ ID NO: 72; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 73, and the amino acid sequence of the light chain is shown in SEQ ID NO: 74; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 75, and the amino acid sequence of the light chain is shown in SEQ ID NO: 76; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 77, and the amino acid sequence of the light chain is shown in SEQ ID NO: 78; b. the amino acid sequence of the heavy chain is shown in SEQ ID NO: 79, and the amino acid sequence of the light chain is shown in SEQ ID NO: 80; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 81, and the amino acid sequence of the light chain is shown in SEQ ID NO: 82; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 83, and the amino acid sequence of the light chain is shown in SEQ ID NO: 84; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 85, and the amino acid sequence of the light chain is shown in SEQ ID NO: 86; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 87, and the amino acid sequence of the light chain is shown in SEQ ID NO: 88; c. the amino acid sequence of the heavy chain is shown in SEQ ID NO: 89, and the amino acid sequence of the light chain is shown in SEQ ID NO: 90; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 91, and the amino acid sequence of the light chain is shown in SEQ ID NO: 92; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 93, and the amino acid sequence of the light chain is shown in SEQ ID NO: 94; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 95, and the amino acid sequence of the light chain is shown in SEQ ID NO: 96; d. the amino acid sequence of the heavy chain is shown in SEQ ID NO: 97, and the amino acid sequence of the light chain is shown in SEQ ID NO: 98; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 99, and the amino acid sequence of the light chain is shown in SEQ ID NO: 100; or The amino acid sequence of the heavy chain is shown in SEQ ID NO: 101, and the amino acid sequence of the light chain is shown in SEQ ID NO: 102; or; The amino acid sequence of the heavy chain is shown in SEQ ID NO: 103, and the amino acid sequence of the light chain is shown in SEQ ID NO: 104; or; The amino acid sequence of the heavy chain is shown in SEQ ID NO: 105, and the amino acid sequence of the light chain is shown in SEQ ID NO: 106; or; The amino acid sequence of the heavy chain is shown in SEQ ID NO: 107, and the amino acid sequence of the light chain is shown in SEQ ID NO: 108; or; The amino acid sequence of the heavy chain is shown in SEQ ID NO: 109, and the amino acid sequence of the light chain is shown in SEQ ID NO: 110; or; The amino acid sequence of the heavy chain is shown in SEQ ID NO: 111, and the amino acid sequence of the light chain is shown in As shown in SEQ ID NO: 112; More preferably, the amino acid sequence of the heavy chain is shown as SEQ ID NO:71, and the amino acid sequence of the light chain is shown as SEQ ID NO:

72.

8. An anti-EGFR antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein: a. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, 128, 130 or 131, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or b. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 126 or 133, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or c. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 127, 132 or 134, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or d. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 127, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; e. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128, 129, 130 or 131, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; Preferably, a. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprising the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 121; or b. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128 or 130, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or c. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 133, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; More preferably, The HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 116, HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO:

121.

9. The anti-EGFR antibody or antigen-binding fragment thereof according to claim 8, wherein: the heavy chain variable region comprises the amino acid sequence of SEQ ID NOs: 138, 135, 136, 137, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149; Preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 138, 142, 144 or 147, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149; More preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:138, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:

149.

10. The anti-EGFR antibody or antigen-binding fragment thereof according to claim 9, which is an antibody fragment; preferably, it is selected from the group consisting of: Fab, Fab', F(ab')2, Fd, Fv, scFv, dsFv and dAb.

11. The anti-EGFR antibody or antigen-binding fragment thereof according to claim 9, wherein the anti-EGFR antibody comprises a heavy chain constant region and a light chain constant region; Preferably, the heavy chain constant region is a human IgG1, IgG2, IgG3 or IgG4 heavy chain constant region, The light chain constant region is a human kappa or lambda light chain constant region; More preferably, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 69 or 186, The light chain constant region comprises the amino acid sequence of SEQ ID NO:

70.

12. The anti-EGFR antibody or antigen-binding fragment thereof according to claim 11, comprising a heavy chain and a light chain, wherein: the heavy chain comprising the amino acid sequence of SEQ ID NO: 153, 150, 151, 152, 154, 155, 156, 157, 158, 159, 160, 161, 162 or 163, and the light chain comprising the amino acid sequence of SEQ ID NO: 164; Preferably, the heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 157, 159 or 162, and the light chain comprises the amino acid sequence of SEQ ID NO: 164; More preferably, the heavy chain comprises the amino acid sequence of SEQ ID NO:153, and the light chain comprises the amino acid sequence of SEQ ID NO:

164.

13. An antigen binding molecule that specifically binds to EGFR and MUC1, comprising: at least one antigen binding moiety that specifically binds to EGFR; and at least one antigen binding moiety that specifically binds to MUC1, The antigen binding module that specifically binds to EGFR comprises a heavy chain variable region EGFR-VH and a light chain variable region EGFR-VL, The antigen binding module that specifically binds to MUC1 comprises a heavy chain variable region MUC1-VH and a light chain variable region MUC1-VL; wherein: a. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, 128, 130 or 131, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or b. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126 or 133, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or c. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 127, 132 or 134, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or d. The HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 127, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118 sequence, and LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; e. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128, 129, 130 or 131, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; Preferably, a. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or b. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128 or 130, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or c. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 133, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; More preferably, a. The HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:

121.

14. The antigen binding molecule that specifically binds to EGFR and MUC1 according to claim 13, wherein: The HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and The LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO:15, LCDR2 comprises the amino acid sequence of SEQ ID NO:16, and LCDR3 comprises the amino acid sequence of SEQ ID NO:

17.

15. The antigen binding molecule that specifically binds to EGFR and MUC1 according to claim 14, wherein: the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, 135, 136, 137, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149; Preferably, the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, 142, 144 or 147, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149; More preferably, the EGFR-VH comprises the amino acid sequence of SEQ ID NO:138, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO:

149. 16 . The antigen binding molecule that specifically binds to EGFR and MUC1 according to claim 15 , wherein the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36; and the MUC1-VL comprises the amino acid sequence of SEQ ID NO:

39.

17. The antigen binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 16, wherein the antigen binding moiety that specifically binds to EGFR or the antigen binding moiety that specifically binds to MUC1 each independently comprises a Titin chain and an Obscurin chain that can form a dimer; Preferably, the Titin chain comprises the amino acid sequence of SEQ ID NO:165, and the Obscurin chain comprises the amino acid sequence of SEQ ID NO:

166.

18. The antigen binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 17, further comprising an Fc region, Preferably, the Fc region is an IgG Fc region, Further preferably, the Fc region is an IgG1 Fc region; More preferably, the Fc region comprises one or more amino acid substitutions that can reduce the binding of the Fc region to Fcγ receptors.

19. The antigen-binding molecule that specifically binds to EGFR and MUC1 according to claim 18, comprising an Fc region, wherein the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, wherein the Fc1 and Fc2 each independently have one or more amino acid substitutions that reduce homodimerization of the Fc region; Preferably, the Fc1 has a protrusion structure according to the pestle-and-mortar technique, and the Fc2 has a hole structure according to the pestle-and-mortar technique; or, the Fc2 has a protrusion structure according to the pestle-and-mortar technique, and the Fc1 has a hole structure according to the pestle-and-mortar technique; More preferably, the amino acid at position 358 of Fc1 is C, and the amino acid at position 370 is W; and the amino acid at position 357 of Fc2 is C, the amino acid at position 374 is S, the amino acid at position 376 is A, and the amino acid at position 415 is V, numbering according to the EU index; or, the amino acid at position 358 of Fc2 is C, and the amino acid at position 370 is W; and the amino acid at position 357 of Fc1 is C, the amino acid at position 374 is S, the amino acid at position 376 is A, and the amino acid at position 415 is V, numbering according to the EU index; Most preferably, the Fc1 comprises the amino acid sequence of SEQ ID NO: 169, and the Fc2 comprises the amino acid sequence of SEQ ID NO: 170; or the Fc1 comprises the amino acid sequence of SEQ ID NO: 182, and the Fc2 comprises the amino acid sequence of SEQ ID NO: 183; or, the Fc2 comprises the amino acid sequence of SEQ ID NO: 169, and the Fc1 comprises the amino acid sequence of SEQ ID NO: 170; or the Fc2 comprises the amino acid sequence of SEQ ID NO: 182, and the Fc1 comprises the amino acid sequence of SEQ ID NO:

183.

20. The antigen binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 19, comprising: an antigen binding moiety that specifically binds to EGFR; and an antigen binding module that specifically binds to MUC1, The antigen binding module that specifically binds to MUC1 is Fab; The antigen binding module that specifically binds to EGFR is a replaced Fab, which comprises a titin chain and an obscurin chain that can form a dimer; Preferably, The antigen binding molecule comprises a first chain having a structure as shown in formula (a), a second chain having a structure as shown in formula (b), a third chain having a structure as shown in formula (c), and a fourth chain having a structure as shown in formula (d), wherein: Formula (a) [MUC1-VH]-[CH1]-[Fc1], Formula (b) [MUC1-VL]-[CL], Formula (c): [EGFR-VH]-[Linker 1]-[Titin]-[Fc2], Formula (d): [EGFR-VL]-[Linker 2]-[Obscurin], in: The linker 1 and linker 2 are the same or different and are peptide linkers; or linker 1 or linker 2 does not exist; The structures shown in formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus; Further preferably, wherein the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and a. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or b. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 126, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 128 or 130, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; or c. the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 133, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 118, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; More preferably, wherein: The MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and The EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, 142, 144 or 147, and the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149; Most preferably, the antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 174, 172, 175, 176 or 177 and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173; Or, the antigen-binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 178, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 179 and A fourth chain comprising the amino acid sequence of SEQ ID NO:

173.

21. The antigen binding molecule that specifically binds to EGFR and MUC1 according to claim 20, wherein the antigen binding molecule comprises: an antigen binding moiety that specifically binds to EGFR; and an antigen binding module that specifically binds to MUC1, The antigen binding module that specifically binds to MUC1 is Fab; The antigen binding module that specifically binds to EGFR is a replaced Fab, which comprises a titin chain and an obscurin chain that can form a dimer; Preferably, The antigen binding molecule comprises a first chain having a structure as shown in formula (a), a second chain having a structure as shown in formula (b), a third chain having a structure as shown in formula (c), and a fourth chain having a structure as shown in formula (d), Formula (a) [MUC1-VH]-[CH1]-[Fc1], Formula (b) [MUC1-VL]-[CL], Formula (c): [EGFR-VH]-[Linker 1]-[Titin]-[Fc2], Formula (d): [EGFR-VL]-[Linker 2]-[Obscurin], in: The linker 1 and linker 2 are the same or different and are peptide linkers; or linker 1 or linker 2 does not exist; The structures shown in formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus; Further preferably, wherein the HCDR1 of the MUC1-VH comprises the amino acid sequence of SEQ ID NO: 12, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 14, and the LCDR1 of the MUC1-VL comprises the amino acid sequence of SEQ ID NO: 15, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; and the HCDR1 of the EGFR-VH comprises the amino acid sequence of SEQ ID NO: 116, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 129, and the LCDR1 of the EGFR-VL comprises the amino acid sequence of SEQ ID NO: 119, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 121; More preferably, wherein said MUC1-VH comprises the amino acid sequence of SEQ ID NO: 36, and said MUC1-VL comprises the amino acid sequence of SEQ ID NO: 39; and said EGFR-VH comprises the amino acid sequence of SEQ ID NO: 138, and said EGFR-VL comprises the amino acid sequence of SEQ ID NO: 149; Most preferably, the antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 171, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 174 and a fourth chain comprising the amino acid sequence of SEQ ID NO: 173; Or the antigen-binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 178, a second chain comprising the amino acid sequence of SEQ ID NO: 74, a third chain comprising the amino acid sequence of SEQ ID NO: 179 and A fourth chain comprising the amino acid sequence of SEQ ID NO:

173.

22. An immunoconjugate comprising: The anti-MUC1 antibody or antigen-binding fragment thereof and the effector molecule according to any one of claims 1 to 7, or The anti-EGFR antibody or antigen-binding fragment thereof and the effector molecule according to any one of claims 8 to 12, or The antigen-binding molecule and effector molecule that specifically bind to EGFR and MUC1 according to any one of claims 13 to 21, wherein the effector molecule is coupled to the anti-MUC1 antibody or antigen-binding fragment thereof, the anti-EGFR antibody or antigen-binding fragment thereof, or an antigen-binding molecule that specifically binds to EGFR and MUC1; Preferably, the effector molecule is selected from the group consisting of anti-tumor agents, immunomodulators, biological response modifiers, lectins, cytotoxic drugs, chromophores, fluorophores, chemiluminescent compounds, enzymes, metal ions, and any combination thereof.

23. An antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof: Y is selected from -O-(CR a R b ) m -CR 1 R 2 -C(O)-, -O-CR 1 R 2 -(CR a R b ) m -, -O-CR 1 R 2 -, -NH-(CR a R b ) m -CR 1 R 2 -C(O)- or -S-(CR a R b ) m -CR 1 R 2 -C(O)-; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group; Or, R a and R b Together with the carbon atom to which it is attached, it forms a cycloalkyl, heterocyclyl, aryl or heteroaryl group; R 1 is selected from halogen, alkyl, haloalkyl, deuterated alkyl, hydroxy, alkoxy, cyano, amino, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl or heteroaryl; R 2 is selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyl group, an alkoxy group, a cyano group, an amino group, a cycloalkyl group, a cycloalkylalkyl group, an alkoxyalkyl group, a heterocyclic group, an aryl group or a heteroaryl group; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl, heterocyclyl, aryl or heteroaryl group; Or, R a and R 2 together with the carbon atom to which it is attached, form a cycloalkyl, heterocyclyl, aryl or heteroaryl group; m is 0, 1, 2, 3 or 4; n is 1 to 10; L is the joint unit; Pc is the anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the anti-EGFR antibody or antigen-binding fragment thereof according to any one of claims 8 to 12, or the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21; Preferably, Pc is the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21.

24. The antibody-drug conjugate represented by the general formula (Pc-LYD) according to claim 23 or a pharmaceutically acceptable salt thereof, wherein: Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-; Among them, R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen and an alkyl group; R 1 is cycloalkyl-alkyl or cycloalkyl; R 2 is selected from the group consisting of a hydrogen atom, a haloalkyl group and a cycloalkyl group; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl group; m is 0, 1, 2, 3 or 4; n is 1 to 10; L is the joint unit; Pc is the anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the anti-EGFR antibody or antigen-binding fragment thereof according to any one of claims 8 to 12, or the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21; Preferably, Pc is the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21.

25. The antibody-drug conjugate represented by the general formula (Pc-LYD) according to claim 23 or 24, or a pharmaceutically acceptable salt thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -, in: L 1 Selected from -(succinimidyl-3-yl-N)-WC(O)-, -CH2-C(O)-NR 3 -WC(O)- and -C(O)-WC(O)-, W is selected from alkylene and alkylene-cycloalkyl, wherein the alkylene or alkylene-cycloalkyl is each independently optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl; L 2 Selected from -NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20; L 3 The peptide residue is composed of 2 to 7 amino acid residues, wherein the amino acid residues are selected from phenylalanine An amino acid residue formed by an amino acid selected from the group consisting of amino acids ... L 4 Selected from -NR 5 (CR 6 R 7 ) t -、-C(O)NR 5 -、-C(O)NR 5 (CH2) t - and chemical bonds, wherein t is 1, 2, 3, 4, 5 or 6; R 3 , R 4 and R 5 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group; R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group; Preferably, the linker unit-L 1 -L 2 -L 3 -L 4 -as follows: L 1 for where s 1 is 2, 3, 4, 5, 6, 7 or 8; L 2 is a chemical bond; L 3 is a tetrapeptide residue; preferably, L 3 is the tetrapeptide residue shown in SEQ ID NO: 180; L 4 For-NR 5 (CR 6 R 7 )t-, where R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2; Wherein the -L- 1 The end is connected to Pc, L 4 Connect the Y end.

26. The antibody-drug conjugate or a pharmaceutically acceptable salt thereof represented by the general formula (Pc-LYD) according to any one of claims 23 to 25, which is the general formula (Pc-L a -YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof: in, Pc is the anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the anti-EGFR antibody or antigen-binding fragment thereof according to any one of claims 8 to 12, or the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21; Preferably, Pc is an antigen binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21; m is 0, 1, 2, 3 or 4; n is 1 to 10; R 1 is cycloalkyl-alkyl or cycloalkyl; R 2 is selected from the group consisting of a hydrogen atom, a haloalkyl group and a cycloalkyl group; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl group; W is selected from alkylene and alkylene-cycloalkyl, wherein the alkylene and alkylene-cycloalkyl are each independently optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl; L 2 Selected from -NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20; L 3 A peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, haloalkyl, deuterated alkyl, alkoxy and cycloalkyl; R 4 and R 5 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, and a hydroxyalkyl group; R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group.

27. A method for preparing a compound of the general formula (Pc-L a -YD) or a pharmaceutically acceptable salt thereof, comprising the following steps: After Pc reduction, it is combined with the general formula (L a -YD) or its salt undergoes coupling reaction to obtain the general formula (Pc-L a -YD) an antibody-drug conjugate or a pharmaceutically acceptable salt thereof; in: Pc is an anti-MUC1 antibody or an antigen-binding fragment thereof according to any one of claims 1 to 7, or The anti-EGFR antibody or antigen-binding fragment thereof according to any one of claims 8 to 12, or the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21; preferably, Pc is the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21; W.L. 2 , L 3 , R 1 , R 2 , R 5 To R 7 , m and n are as defined in claim 26.

28. A pharmaceutical composition comprising: The anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, the anti-EGFR antibody or antigen-binding fragment thereof according to any one of claims 8 to 12, the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21, the antibody-drug conjugate or pharmaceutically acceptable salt thereof according to any one of claims 23 to 26; and One or more pharmaceutically acceptable carriers, diluents or excipients.

29. An isolated nucleic acid encoding the anti-MUCl antibody or antigen-binding fragment thereof of any one of claims 1 to 7 or the anti-EGFR antibody or antigen-binding fragment thereof of any one of claims 8 to 12.

30. A host cell comprising the isolated nucleic acid of claim 29.

31. A method for preventing or treating a disease, the method comprising the steps of: administering to a subject a preventively or therapeutically effective amount of the anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, the anti-EGFR antibody or antigen-binding fragment thereof according to any one of claims 8 to 12, the antigen-binding molecule that specifically binds to EGFR and MUC1 according to any one of claims 13 to 21, the antibody-drug conjugate or pharmaceutically acceptable salt thereof according to any one of claims 23 to 26, or the pharmaceutical composition according to claim 28; Preferably, the disease is a tumor; More preferably, the disease is selected from the group consisting of: astrocytoma, glioblastoma, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, fallopian tube cancer, gallbladder cancer, gastric cancer, head and neck cancer, idiopathic myelofibrosis, kidney cancer, leukemia, liver cancer, esophageal cancer, lung cancer, medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, multiple myeloma, neuroblastoma, oligodendroglioma, ovarian cancer, peritoneal tumors, pancreatic cancer, polycythemia vera, primary neuroectodermal tumors, prostate cancer, retinoblastoma, sarcoma, squamous cell carcinoma, thyroid cancer, endometrial cancer, vestibular schwannoma, blastoma, vulvar cancer, thymoma, testicular cancer, bile duct cancer, pheochromocytoma, paraganglioma and adenoid cystic carcinoma; Most preferably, the disease is selected from the group consisting of lung cancer, head and neck cancer, esophageal cancer, breast cancer, pancreatic cancer, prostate cancer, thyroid cancer, gastric cancer, ovarian cancer, colorectal cancer, liver cancer, gallbladder cancer, kidney cancer, cervical cancer and bladder cancer.